HSCI 180 · Lesson 1

Drugs and Society: Concepts, Patterns of Use and Language

Drugs and Society

Learning objectives for this lesson:

  1. Define a psychoactive substance and distinguish the medical, pharmacological and legal meanings of the word “drug”.
  2. Classify common psychoactive substances into drug classes and into the legal categories set by Canadian law as of 2026.
  3. Explain why licit and illicit categories are socially and legally constructed, and weigh the evidence on whether legal status reflects harm.
  4. Describe the five stages of Health Canada’s substance use spectrum and explain why a spectrum describes substance use more accurately than a division between “use” and “abuse”.
  5. Explain how the boundaries between stages of the spectrum are drawn, calculate weekly standard drinks against Canada’s 2011 drinking guidelines and the 2023 Guidance on Alcohol and Health, state the DSM-5 definition and severity levels of substance use disorder, and evaluate the strengths and limits of the spectrum.
  6. Read past-year prevalence estimates from the Canadian Substance Use Survey and the UNODC World Drug Report, and convert a survey percentage into an estimated number of people.
  7. Identify the groups that household and school surveys miss and name data sources that help fill those gaps.
  8. Distinguish self, social and structural stigma, use person-first, non-stigmatizing language, and explain what experiments on stigmatizing labels can and cannot show about clinicians’ judgements.
  9. Analyze how the words used in laws and by public agencies shape drug policy in Canada.
  10. Apply the categories, spectrum, survey evidence and language of this lesson to a Canadian case of drug-related harm.

This course was developed by Dr. Kiffer G. Card.

Lesson 1 · HSCI 180

Drugs and Society: Concepts, Patterns of Use and Language

A short guided introduction before you work through the lesson at your own pace.

Drugs and Society
Why start here

Most people use psychoactive substances

Most people who drink coffee or wine would not say they “use drugs”. This lesson asks why, and what the answer means for health and policy.

84%of people aged 15 and older in Canada used at least one substance in the past year (2025 survey; Health Canada, 2026)
The road map

Four sections, four lenses

1 · What counts as a drug

Psychoactive substances, drug classes and Canada’s legal categories.

2 · The spectrum of use

From non-use through beneficial, lower-risk and higher-risk use to substance use disorder.

3 · Patterns of use

Canadian and global survey data, and the people surveys miss.

4 · Language and stigma

Person-first terms, experimental evidence and how words shape policy.

Real examples

Canadian cases you will meet again

Canadian Substance Use Survey
Cannabis Act (2018)
Guidance on Alcohol and Health (2023)
BC decriminalization exemption (2023 to 2026)
BC Coroners Service reports
Vancouver Area Network of Drug Users
Section 1 of 5

What Counts as a Drug: Psychoactive Substances and Their Legal Categories

⏱ Estimated reading time: 35 minutes
Section 1 of 5

What Counts as a Drug

Psychoactive substances and the legal categories Canada places them in.

Definitions

Three meanings of “drug”

Medicine

A product used to diagnose, treat or prevent disease.

Psychoactive substance

Any substance that changes mental processes. This course uses this meaning.

Illegal substance

A substance whose supply is prohibited. This meaning changes when laws change.

Psychoactive drugs are substances that, when taken in or administered into one’s system, affect mental processes.World Health Organization
Drug classes

A map of the main classes

Depressants

Alcohol, benzodiazepines

Opioids

Morphine, fentanyl

Stimulants

Caffeine, nicotine, cocaine

Cannabis

THC and CBD products

Psychedelics

Psilocybin, LSD

Dissociatives

Ketamine

Inhalants

Solvents, nitrous oxide

Lessons 4 to 7

Each class in depth

Canadian law, October 2026

How the law sorts substances

Controlled Drugs and Substances Act

Schedule I: opioids, cocaine, methamphetamine. Schedule III: psilocybin, LSD, methylphenidate. Schedule IV: benzodiazepines. Possession of Schedule I to III substances without authorization is an offence.

Regulated products

Cannabis Act (in force 17 October 2018), Tobacco and Vaping Products Act, and provincial and territorial alcohol laws.

Case 1.1

One substance, several statuses

Hydromorphone

Legal on a prescription; an offence to possess without one (Schedule I).

Cannabis

Legal from a licensed store; an offence to possess if an adult knows it is illicit (Cannabis Act, s. 8).

Source and substance together set the legal category (Canadian law as of October 2026).

Evidence

Do legal categories follow harm?

72 / 100Alcohol’s overall harm score, highest of 20 drugs rated by one UK expert panel (Nutt et al., 2010)

The panel concluded that its scores matched UK legal classes poorly.

A critique argued that one score hides different harms and ignores how policy shapes harm (Caulkins et al., 2011).

Research on comparing drug harms is evolving.

Carry forward

From substances to patterns of use

  • Pharmacology defines a psychoactive substance by its effect on the mind.
  • Canadian law sorts substances by schedule, prescription and source.
  • Legal categories are socially constructed and do not follow harm alone.
  • Section 2 describes how people use substances, using Health Canada’s spectrum.

Introduction

Most people in Canada used at least one psychoactive substance in the past year. In 2025, Health Canada’s Canadian Substance Use Survey estimated that 84 percent of people aged 15 and older, about 29.3 million people, had used at least one substance in the previous 12 months, and alcohol was by far the most common (Health Canada, 2026). Many of these people would not describe themselves as people who “use drugs”. The word drug calls to mind something illegal, dangerous or foreign, while a morning coffee, a glass of wine or a prescribed painkiller feels ordinary. That difference in feeling is the subject of this section.

The section begins with a definition of a psychoactive substance and the classes into which pharmacologists group them. It then examines how Canadian law sorts the same substances into categories (legal products, prescription medicines and controlled substances) and why those categories change over time. The aim is a vocabulary precise enough to carry through the rest of the course: Lesson 3 builds the shared pharmacology on it, Lessons 4 to 7 apply it to each drug class, and Lessons 11 and 12 return to the legal categories when they examine drug control and its alternatives.

Learning Objectives

  • 1.1 Define a psychoactive substance and distinguish the medical, pharmacological and everyday legal meanings of the word “drug”.
  • 2.1 Name the main drug classes (depressants, inhalants, opioids, stimulants, cannabis, psychedelics and dissociatives) and give a Canadian example of each.
  • 2.2 Describe how Canadian law sorts substances into regulated, prescribed and controlled categories, using the Controlled Drugs and Substances Act, the Cannabis Act and the Tobacco and Vaping Products Act, and distinguish prohibition, decriminalization, legal regulation and exemptions.
  • 3.1 Explain why the licit and illicit categories are socially and legally constructed, and weigh the evidence on whether legal status follows harm.
  • 3.2 Explain how culture, history and power have shaped drug categories in Canada.

1.1 Psychoactive Substances

The World Health Organization defines psychoactive drugs as substances that, “when taken in or administered into one’s system, affect mental processes”, such as perception, consciousness, cognition, mood or emotion (World Health Organization, n.d.). The definition is pharmacological. It asks what a substance does to the brain and the mind, and it says nothing about whether the substance is legal, prescribed, sold in a grocery store or traded in an unregulated market. The WHO notes that psychoactive drugs belong to a broader category of psychoactive substances that also includes alcohol and nicotine.

Confusion about drugs often begins with the word itself, which carries at least three meanings in everyday English. The box that follows separates them, because a sentence that is true under one meaning can be false under another.

Three meanings of “drug”

A medicine. In a pharmacy, a drug is any product used to diagnose, treat or prevent disease. An antibiotic or insulin is a drug in this sense, although neither acts on the mind.

A psychoactive substance. In pharmacology and in this course, a drug is any substance that changes mental processes. Caffeine, alcohol, nicotine, cannabis, prescribed opioids and cocaine are all drugs in this sense.

An illegal substance. In everyday speech and in phrases such as the “war on drugs”, a drug is a substance whose supply is prohibited. This meaning reflects law and social judgement, and it changes when laws change. This course calls these substances controlled or, when they are sold outside any regulated system, part of the unregulated drug supply.

This course uses “drug” and “substance” in the second sense unless the text says otherwise. The choice places a cup of coffee and a line of cocaine in the same analytic category, so that the differences between them (dose, speed of action, risk, legal status and social meaning) become questions to investigate.

Caffeine shows how ordinary psychoactive use can be. It is the active ingredient in coffee, tea, cola and energy drinks, and it raises alertness by acting on the brain. Health Canada regulates the amount of caffeine that may be added to foods and advises that healthy adults consume no more than 400 milligrams a day, that people who are pregnant, breastfeeding or planning a pregnancy consume no more than 300 milligrams, and that children and adolescents consume no more than 2.5 milligrams per kilogram of body weight (Health Canada, 2025a). A regular 355-millilitre can of cola contains about 36 to 46 milligrams. These numbers are a reminder that a substance can be legal, widely used and socially approved while still carrying limits based on dose. The same logic of dose and context applies to every substance in this course.

With the subject of the course defined and the three meanings of “drug” separated, the next step is to group psychoactive substances by their main effects.

2.1 The Main Drug Classes

Pharmacologists group psychoactive substances into classes according to their main effects on the central nervous system (the brain and spinal cord) and the receptors through which they act. A receptor is a protein on a nerve cell that a chemical messenger, or a drug that resembles it, attaches to, much as a key fits a lock. Lesson 3 explains receptors in detail. For now, the classes provide a map. Table 1.1 lists the classes this course uses, with examples and the lesson that develops each one.

Table 1.1. The main classes of psychoactive substances used in this course, with their main effects, common examples and the lesson that develops each class.

ClassMain effectExamplesLesson
DepressantsSlow activity in the central nervous system; many enhance the calming messenger GABAAlcohol, benzodiazepines such as diazepam and lorazepam, barbiturates, GHB4
InhalantsProduce brief intoxication when vapours or gases are breathed inVolatile solvents, nitrous oxide4
OpioidsAct on opioid receptors to relieve pain; at higher doses they slow breathingMorphine, codeine, oxycodone, hydromorphone, fentanyl, heroin (diacetylmorphine)5
StimulantsIncrease alertness and energy; most raise the activity of messengers such as dopamine and noradrenaline, while caffeine blocks the drowsiness-promoting messenger adenosineCaffeine, nicotine, cocaine, amphetamine, methamphetamine, methylphenidate6
CannabisActs mainly on cannabinoid receptors, producing relaxation and altered perceptionDried cannabis, edibles and extracts containing THC and CBD7
PsychedelicsAlter perception, thought and mood, mainly through serotonin receptorsPsilocybin, LSD7
DissociativesProduce detachment from the body and surroundings by blocking a type of glutamate receptorKetamine, PCP7

Classes are a convenience, and some substances fit more than one. MDMA has both stimulant and perception-altering effects, nicotine is a stimulant that most people meet through tobacco or vaping, and alcohol is a depressant that can feel stimulating at low doses. The classes also say nothing about legal status. Caffeine and cocaine are both stimulants. Alcohol and lorazepam are both depressants. The legal system sorts them very differently, and the next subsection examines how.

2.2 Licit, Illicit, Prescribed and Regulated

A licit substance is one whose production, sale and possession are permitted by law, usually under conditions. An illicit substance is one that is produced, sold or held outside what the law permits. These words describe a relationship between a substance, a person and the law at a particular time, and the same molecule can be licit in one hand and illicit in another. In Canada, several statutes do the sorting.

2.2.1 The Laws That Sort Substances in Canada

The Controlled Drugs and Substances Act (CDSA), assented to on 20 June 1996, is the main federal drug law. It lists substances in numbered schedules, which are legal lists that attach different rules to the substances they contain. Schedule I includes opium-derived and synthetic opioids (codeine, morphine, oxycodone, hydromorphone, methadone and fentanyl), coca and cocaine, and amphetamine and methamphetamine. Schedule III includes methylphenidate, psilocybin and LSD. Schedule IV includes barbiturates and benzodiazepines (Controlled Drugs and Substances Act, 1996). A substance listed under the CDSA is called a controlled substance.

The schedules carry different consequences. Under section 4(1), possessing a substance in Schedule I, II or III is an offence “except as authorized under the regulations”, for example with a prescription. Possession of a Schedule IV substance is not included in that section, although trafficking in substances from Schedules I to V is an offence under section 5. Schedule V lists new substances that are controlled temporarily while the government assesses them. In October 2026 it listed two new substances, spirobrorphine and spirochlorphine, for the period from 5 June 2026 to 4 June 2027. Lesson 7 explains how early warning systems detect such substances.

Other laws cover the substances that adults may buy legally. The Cannabis Act came into force on 17 October 2018. It permits adults aged 18 and older to possess up to the equivalent of 30 grams of dried cannabis in a public place, lets provinces and territories run the sale of cannabis, and allows them to raise the minimum age (Cannabis Act, 2018; Department of Justice Canada, 2021). The Tobacco and Vaping Products Act, first passed in 1997 and renamed in 2018 when vaping products were added, regulates the manufacture, sale, labelling and promotion of tobacco and vaping products (Tobacco and Vaping Products Act, 1997). Alcohol is governed mainly through provincial and territorial policies, including the systems that control its sale and the minimum legal age, together with a smaller set of federal policies; the Canadian Alcohol Policy Evaluation project assesses both levels of government (Canadian Institute for Substance Use Research, n.d.). Table 1.2 brings these rules together.

Table 1.2. How Canadian law sorted common psychoactive substances as of October 2026, with the main law that applies to each category.

CategoryWhat the law permitsExamplesMain law
Regulated consumer productsSale under licence or product rules, with age limits and controls on promotionAlcohol, commercial tobacco and vaping products, cannabis from licensed stores, caffeine in foodsProvincial and territorial alcohol laws; Tobacco and Vaping Products Act; Cannabis Act; Health Canada food rules
Prescribed controlled medicinesPossession and use when prescribed and dispensed through the medical systemHydromorphone and oxycodone (Schedule I), methylphenidate (Schedule III), lorazepam (Schedule IV)Controlled Drugs and Substances Act and its regulations
Controlled substances without authorizationPossession of Schedule I to III substances and trafficking in Schedule I to V substances are offencesCocaine, methamphetamine, fentanyl from the unregulated supply, psilocybinControlled Drugs and Substances Act, sections 4 and 5
Temporarily controlled new substancesListed for a set period while the substance is assessedSpirobrorphine and spirochlorphine (5 June 2026 to 4 June 2027)Controlled Drugs and Substances Act, Schedule V

Figure 1.1 summarizes the logic behind Table 1.2. Three separate questions, one about pharmacology, one about medical approval and one about legal control, combine to place a substance in a category.

1. Pharmacology Does it act on the mind? Caffeine: yes Alcohol: yes Insulin: no 2. Medicine Is it prescribed? Hydromorphone: yes Methylphenidate: yes Beer: no 3. Law How is supply controlled? Cannabis: licensed sale Cocaine: Schedule I Lorazepam: Schedule IV Result: a social and legal category regulated, prescribed or controlled, and open to change
Figure 1.1. Three separate questions combine to place a substance in a category. Pharmacology describes what a substance does, while medical approval and law describe how a society has chosen to manage it. The examples reflect Canadian law as of October 2026.

2.2.2 Prohibition, Decriminalization, Legal Regulation and Exemptions

Four policy terms recur throughout the course, and they are easy to confuse. The flip cards that follow define each one with a Canadian example. Lesson 12 compares them in depth.

ProhibitionClick to explore
DecriminalizationClick to explore
Legal regulationClick to explore
Section 56 exemptionClick to explore

Case 1.1 applies these categories to two real examples in which the same substance can be legal or illegal depending on where it came from.

Case 1.1: One substance, several legal statuses

Hydromorphone is an opioid pain medicine listed in Schedule I of the Controlled Drugs and Substances Act. When a physician or nurse practitioner prescribes it and a pharmacy dispenses it, a patient possesses it legally. If the same tablets are sold or given to someone without a prescription, the person who receives them commits a possession offence under section 4(1) and the person who passes them on may commit trafficking under section 5. In 2025, the Canadian Substance Use Survey estimated that 3 percent of people aged 15 and older, about 1.2 million people, had obtained an opioid, sedative or stimulant usually available only by prescription from outside the medical system in the previous year. Of those, 79 percent obtained them from friends or family with permission (Health Canada, 2026).

Cannabis shows the same pattern under a different law. Section 8(1)(b) of the Cannabis Act makes it an offence for an adult “to possess any cannabis that they know is illicit cannabis”. A 25-year-old who buys cannabis from a licensed provincial store possesses it legally. The same person holding cannabis they know came from an unlicensed seller does not. The plant, its THC content and its effects can be identical in both cases. The legal category depends on the supply chain.

Canadian law therefore sorts substances by schedule, by medical authorization and by source. The next question is whether these categories reflect how harmful the substances are.

3.1 Why Legal Categories Do Not Follow Harm Alone

Sociologists describe drug categories as socially constructed. The phrase means that people, institutions and laws create the categories “legal drug”, “medicine” and “illicit drug”, and that these categories have changed across history, while the chemical actions of the substances have stayed the same. The idea accepts that drugs have real effects and real risks, and it directs attention to the decisions, interests and beliefs that turned those effects into legal categories.

One way to test the idea is to compare legal status with expert estimates of harm. The two tabs that follow present an influential study and a strong critique of it.

Nutt, King and Phillips (2010) convened members of the Independent Scientific Committee on Drugs in the United Kingdom to score 20 drugs on 16 criteria, nine describing harms to the person who uses the drug and seven describing harms to others. Each drug received an overall score out of 100. Alcohol scored highest overall (72), followed by heroin (55) and crack cocaine (54). Heroin, crack cocaine and methamphetamine were most harmful to the individual, while alcohol was most harmful to others. The authors concluded that their findings “correlate poorly” with the United Kingdom’s drug classification, which is not based simply on considerations of harm.

Caulkins, Reuter and Coulson (2011) argued that ranking drugs by a single harm score is “fundamentally flawed”. A single number hides harms that cannot be compared on one scale, such as deaths, family disruption and crime. The rankings ignore benefits for most drugs. The harms of a drug also depend on the policy regime: alcohol’s harms reflect its legal availability, and the harms of heroin partly reflect prohibition. Their conclusion was that harm should be displayed on several dimensions to inform human judgement, and that even a perfect ranking would not be sufficient to decide which drugs to schedule.

Read together, the two papers frame a debate. The 2010 panel’s scores matched the United Kingdom’s legal classes poorly, with alcohol the clearest example, yet turning harm rankings directly into law would be difficult because harm has many dimensions and is itself shaped by law. Later panels that used the same method have produced related but different results. A Canadian panel again scored alcohol as the most harmful drug overall (Crépault et al., 2026), while a panel in the United States scored fentanyl highest and concluded that US drug policy did not align with its ratings (Broman et al., 2025). These rankings rest on expert judgement and on each country’s policy context, and research on comparing drug harms is still evolving. Students should be cautious of anyone who claims that a substance is illegal “because it is the most dangerous” or that it should be legal “because it is less harmful than alcohol”. Each claim compresses a complex comparison into a single ranking.

3.2 Culture, History and Power

Culture shapes categories as much as law does. The First Nations Health Authority (FNHA) in British Columbia makes “a clear distinction between respecting the use of traditional tobacco and the consumption of commercial tobacco”. It describes traditional tobacco as “a medicine to be treated with great respect”, used in ceremony and prayer to connect with the land and with ancestors, and it encourages people to reduce or stop using commercial tobacco, which it describes as doing immense damage to the body (First Nations Health Authority, 2022). Both are called tobacco, yet their meaning, their use and their place in a community’s life differ.

History shows that categories also reflect who is thought to use a substance. Canada’s Opium Act of 1908 is one of the country’s first drug laws. Lesson 2 examines how anti-Asian racism shaped it and how racialized fears drove the drug panics of the 1920s. Cannabis possession was a criminal offence for decades before the Cannabis Act, and a federal commission recommended repealing that offence in the early 1970s; Lesson 2 traces that history. Category changes continue. British Columbia’s decriminalization exemption began in 2023 and ended in 2026. The pharmacology of cannabis, opioids and cocaine stayed the same through these changes, while the response of Canadian governments to the people who use them shifted.

Interactive 1.1 asks you to apply the Canadian categories to ten examples. Some examples involve the same substance in two situations, which is where the logic of Case 1.1 matters.

Interactive 1.1
Sort substances into Canada’s legal categories (as of October 2026)
For each hypothetical example, choose the category that best describes its legal status for the person described. Then select “Check my sorting” to see feedback. The categories are: A, a regulated consumer product; B, a controlled medicine possessed legally on a prescription; C, possession without authorization is an offence; D, a controlled substance whose simple possession is not itself an offence.

The sorting exercise shows that a legal category is a statement about a substance, a person, a source and a date.

Summary

This section defined a psychoactive substance as any substance that changes mental processes, and separated that pharmacological meaning from the medical and legal meanings of “drug”. It grouped substances into depressants, inhalants, opioids, stimulants, cannabis, psychedelics and dissociatives. It then showed how the Controlled Drugs and Substances Act, the Cannabis Act, the Tobacco and Vaping Products Act and provincial alcohol laws sort substances by schedule, medical authorization and source, and why the resulting categories reflect culture, history and policy choices as well as harm. It also distinguished prohibition, decriminalization and legal regulation, which Lesson 12 compares. Legal categories are only one way of describing substance use. Section 2 introduces another: Health Canada’s spectrum, which describes how a person uses a substance, from non-use to substance use disorder.

Key Takeaways

  • 1.1 A psychoactive substance is any substance that changes mental processes such as perception, consciousness, cognition, mood or emotion, a pharmacological definition that says nothing about legal status. The word “drug” can also mean a medicine used to diagnose, treat or prevent disease, or an illegal substance whose supply is prohibited, and a sentence that is true under one meaning can be false under another. Caffeine shows that a legal, widely used substance is still psychoactive and still carries limits based on dose.
  • 2.1 Pharmacologists group psychoactive substances by their main effects into depressants, inhalants, opioids, stimulants, cannabis, psychedelics and dissociatives. Some substances, such as MDMA, have effects that cross classes, and the classes say nothing about legal status: caffeine and cocaine are both stimulants.
  • 2.2 The Controlled Drugs and Substances Act lists controlled substances in schedules, and possession of a Schedule I to III substance without authorization is an offence, while the Cannabis Act, the Tobacco and Vaping Products Act and provincial and territorial alcohol laws regulate legal products. The same substance can be legal or illegal depending on prescription and source, as hydromorphone and cannabis show. Prohibition, decriminalization, legal regulation and section 56 exemptions are distinct policy approaches.
  • 3.1 Drug categories are socially constructed: people, institutions and laws create them, and they change while the chemistry stays the same. Nutt, King and Phillips (2010) ranked alcohol as the most harmful of 20 drugs overall, so in this study legal status did not follow expert harm estimates, but Caulkins, Reuter and Coulson (2011) argued that a single harm score hides harms that cannot be compared, ignores benefits and overlooks how policy itself shapes harm.
  • 3.2 Culture, history and power shape categories as much as law does. The First Nations Health Authority distinguishes traditional tobacco, a medicine used in ceremony and prayer, from commercial tobacco; anti-Asian racism shaped the Opium Act of 1908; and British Columbia’s decriminalization exemption began in 2023 and ended in 2026 while the pharmacology of the substances stayed the same.

Reflection

Consider three facts about Canadian law and evidence as of October 2026. First, hydromorphone is a Schedule I opioid under the Controlled Drugs and Substances Act: a patient holding it on their own prescription possesses it legally, while a person holding the same tablets without a prescription commits an offence. Second, section 8(1)(b) of the Cannabis Act makes it an offence for an adult to possess cannabis they know is illicit, although the same adult may legally possess cannabis bought from a licensed store. Third, Nutt, King and Phillips (2010) scored alcohol, a legal drug, as the most harmful of 20 drugs overall (72 out of 100), ahead of heroin (55) and crack cocaine (54), while Caulkins, Reuter and Coulson (2011) argued that a single harm score hides harms that cannot be compared, ignores benefits and overlooks how policy itself shapes harm. In 150 to 250 words, explain what these facts show about how legal drug categories are made, and state whether you think legal status should follow expert harm rankings, using one point from each paper.

Model answer

The first two facts show that a legal category is not a property of a molecule. Hydromorphone and cannabis are legal or illegal depending on who holds them, where they came from and whether a prescriber or licensed store stood in the supply chain. The tablets in a patient’s cabinet and the tablets bought from a neighbour are chemically identical; the law sorts the relationship between the person, the source and the state. That is what it means to call the categories socially and legally constructed.

The third fact suggests that these categories do not simply track harm. The UK expert panel convened by Nutt and colleagues ranked alcohol, which is legally sold, above heroin and crack cocaine, mostly because of its harm to other people. One panel’s scores cannot settle the question, but they give good reason to doubt claims that a drug is illegal simply because it is dangerous.

I do not think legal status should simply follow a harm ranking, however. Caulkins and colleagues point out that alcohol’s harms partly reflect its legal availability and heroin’s partly reflect prohibition, so a ranking built under one set of laws cannot tell us what would happen under another. I would use harm evidence displayed on several dimensions, together with evidence about how each policy changes those harms, and judge each substance separately.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: According to the World Health Organization definition used in this lesson, what makes a substance psychoactive?

The WHO definition is pharmacological: a psychoactive substance changes mental processes such as perception, consciousness, cognition or mood. Being listed in a schedule is a legal status, and the lesson stresses that legal status and psychoactive action are separate questions; caffeine and alcohol are psychoactive and unscheduled.

Question 2: Under section 4(1) of the Controlled Drugs and Substances Act, which situation is a possession offence as of October 2026?

Section 4(1) makes possession of Schedule I, II and III substances an offence except as authorized, and psilocybin is in Schedule III. Lorazepam is the tempting choice, but Schedule IV substances are not covered by section 4(1), although giving or selling them can be trafficking under section 5. Licensed cannabis and prescribed hydromorphone are possessed legally.

Question 3: Which statement best describes the claim that drug categories are socially constructed?

Social construction means that the categories themselves (legal product, medicine, illicit drug) are made by people and institutions and shift over time, while the pharmacology stays the same. The idea accepts that drugs have real effects, so the option claiming effects come only from expectations misstates it.

Question 4: Nutt, King and Phillips (2010) scored alcohol as the most harmful of 20 drugs overall. What was the main point of the critique by Caulkins, Reuter and Coulson (2011)?

Caulkins and colleagues argued that a single score masks harms that cannot be compared on one scale, usually ignores benefits, and treats harm as fixed although it depends on the policy regime. They did not dispute that alcohol harms others; Nutt and colleagues found alcohol was the most harmful drug to others.
Section 2 of 5

Health Canada’s Spectrum of Substance Use: From Non-Use to Substance Use Disorder

⏱ Estimated reading time: 35 minutes
Section 2 of 5

The Spectrum of Substance Use

From non-use through beneficial, lower-risk and higher-risk use to substance use disorder.

Health Canada, 2022

Five stages, and movement between them

Non-use
Beneficial use
Lower-risk use
Higher-risk use
Substance use disorder

People can move back and forth between stages over time.

Beneficial and lower-risk use

Benefits, and guidelines that set limits

Beneficial use

Medication taken as prescribed; ceremonial tobacco use such as smudging.

Lower-risk use

Use within guidelines: Canada’s Guidance on Alcohol and Health (2023); Lower-Risk Cannabis Use Guidelines (2017, 2022).

Case 1.2

The boundary of lower-risk drinking moved

Weekly standard drinks (Eq 1.1)
\[ W = d \times k \]

2011 guidelines

Up to 10 drinks a week (women) or 15 (men).

2023 Guidance

Low: 2 or fewer. Moderate: 3 to 6. Increasingly high: 7 or more.

Higher-risk use

Where the risk comes from

Amount

Binge drinking, rising frequency

Context

Impaired driving

Combination

19% combined substances in 2025

Supply

Unknown content of unregulated drugs

DSM-5

Substance use disorder

Mild

2 or 3 criteria

Moderate

4 or 5 criteria

Severe

6 or more criteria

At least 2 of 11 criteria within 12 months. In 2025, 4% of people who had used a substance in the past three months were at high risk of dependence (Health Canada).

Carry forward

From individuals to populations

  • The spectrum runs from non-use to substance use disorder, and people move along it.
  • Guidelines set the boundary of lower-risk use, and the boundary can move.
  • Most substance use does not meet the criteria for a disorder.
  • Section 3 measures patterns of use across Canada and the world.

Introduction

Section 1 sorted substances by their effects and their legal status. That approach describes the substance. It says little about the person using it: how often, how much, in what setting and with what consequences. Two people can drink the same beer, one with dinner on a Friday and one before driving home, and the substance is identical while the risk is not. Public health agencies therefore describe patterns of use as well as substances.

This section introduces the substance use spectrum published by Health Canada in 2022, which arranges patterns of use from non-use through beneficial, lower-risk and higher-risk use to substance use disorder. It then examines how the boundaries between stages are drawn, using Canada’s alcohol guidance as a worked case, and how the clinical diagnosis of substance use disorder is defined. HSCI 402 develops screening, diagnosis and treatment; the aim here is a shared vocabulary for describing patterns of use.

Learning Objectives

  • 4.1 Describe the five stages of Health Canada’s substance use spectrum (non-use, beneficial use, lower-risk use, higher-risk use and substance use disorder), and explain why a spectrum describes substance use more accurately than a division between “use” and “abuse”.
  • 4.2 Describe non-use and beneficial use, with an example of each.
  • 5.1 Explain how the boundary of lower-risk use is drawn, using the change from Canada’s 2011 drinking guidelines to Canada’s Guidance on Alcohol and Health (2023), and calculate weekly standard drinks.
  • 5.2 Identify the sources of risk that place a pattern of use at the higher-risk stage, including the place of illegal drug use on the spectrum.
  • 5.3 Describe how the DSM-5 defines substance use disorder and its severity levels, and explain why most substance use does not meet that definition.
  • 5.4 Evaluate the strengths and limits of the spectrum, including its treatment of illegal drug use, and place patterns of use on it.

4.1 From a Binary to a Spectrum

For much of the twentieth century, both clinical and everyday language divided people into those who used substances acceptably and those who “abused” them. The word survived in clinical manuals. The fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), published in 1994, distinguished “substance abuse” from “substance dependence”. When the fifth edition (DSM-5) appeared in May 2013, it combined them into a single condition, substance use disorder, with severity levels from mild to severe (National Institute on Alcohol Abuse and Alcoholism [NIAAA], 2021). Section 4 explains why the word “abuse” has also fallen out of favour in public health language.

A two-category scheme leaves out much of the variation that matters for health. It cannot distinguish a person who takes a prescribed opioid after surgery from a person who drinks one glass of wine a week, or either of them from a person who drinks heavily every weekend but has no diagnosable disorder. A spectrum arranges these patterns along a line from no use to a disorder, with intermediate stages that carry different levels of benefit and harm.

Health Canada published its Substance Use Spectrum infographic on 10 May 2022. It states that “substance use is different for everyone and can be viewed on a spectrum with varying stages of benefits and harms”, and that people can move back and forth between stages over time (Health Canada, 2022a). Figure 1.2 draws the five stages, and Table 1.3 lists the description and examples Health Canada gives for each.

Benefits and harms change along the spectrum Non-use abstinence Beneficial use Lower-risk use Higher-risk use Substance use disorder (addiction) People can move back and forth between stages over time. The same person can sit at different stages for different substances.
Figure 1.2. The five stages of Health Canada’s substance use spectrum, redrawn from the 2022 infographic (Health Canada, 2022a). The colours mark increasing potential for harm and are a teaching device; the stages describe categories of pattern and have no exact positions on a measured scale.

Table 1.3. The stages of Health Canada’s substance use spectrum, with Health Canada’s descriptions and examples (Health Canada, 2022a).

StageHealth Canada’s descriptionHealth Canada’s examples
Non-useAvoiding substance use (abstinence)Not using drugs, tobacco or alcohol
Beneficial use“Use that can have positive health, social, or spiritual effects”Taking medication as prescribed; ceremonial or religious use of tobacco, such as smudging
Lower-risk useUse with minimal impact on the person, their family, friends and othersDrinking within low-risk drinking guidelines; using cannabis according to the lower-risk cannabis use guidelines
Higher-risk useUse that has a harmful and negative impact on the person, their family, friends and othersBinge drinking, impaired driving, illegal drug use, increasing the quantity or frequency of use, combining substances
Addiction (substance use disorder)“A treatable medical condition that affects the brain”, involving compulsive, continuous use despite negative impactsBeing unable to stop using drugs, tobacco or alcohol even when wanting to

The infographic adds several qualifications. Effects vary with sex, age, weight, tolerance, health conditions and the substance used. The safest approach is to avoid use, and some substances carry serious risk at any level. For children and young adults, who are especially vulnerable, there may be no level of beneficial or lower-risk use. Recovery from addiction is possible and looks different for everyone (Health Canada, 2022a). The rest of this section takes the stages in turn.

4.2 Non-Use and Beneficial Use

Non-use is the simplest stage, but it is neither rare nor fixed. In the 2025 Canadian Substance Use Survey, 84 percent of people aged 15 and older had used at least one substance in the past year, which means about one person in six had used none of the substances the survey asked about (Health Canada, 2026). Many people move between non-use and other stages over a lifetime, for example by stopping alcohol during pregnancy or after a health scare.

Beneficial use is the stage that most surprises students, because it treats some substance use as positive. Health Canada’s two examples point to different kinds of benefit. Taking a medication as prescribed brings a health benefit: an opioid after surgery, a stimulant medication for attention-deficit/hyperactivity disorder, or a benzodiazepine for a short course of severe anxiety. Ceremonial use of tobacco, such as smudging, brings a spiritual and social benefit. As Section 1 noted, the First Nations Health Authority distinguishes traditional tobacco, which it describes as a medicine used with respect in ceremony and prayer, from commercial tobacco (First Nations Health Authority, 2022). Beneficial use is not risk-free. A prescribed medicine can still cause side effects or dependence, which is why prescribing follows rules and why Lesson 4 examines deprescribing benzodiazepines in older adults.

Non-use and beneficial use are the two stages at the left of the spectrum. The next stage, lower-risk use, is the one whose boundary is most often set by formal guidelines.

5.1 Lower-Risk Use and How Its Boundary Is Drawn

Lower-risk use is defined by reference to guidelines. Health Canada’s examples are drinking within the low-risk drinking guidelines and using cannabis according to the lower-risk cannabis use guidelines. A guideline turns research on dose and harm into advice about amounts, frequency and settings. Because research and judgements about acceptable risk both change, the boundary of lower-risk use can move, as Case 1.2 shows.

What is a standard drink?

Alcohol guidance counts standard drinks, each containing the same amount of pure alcohol. In Canada, a standard drink is 17.05 millilitres, or 13.45 grams, of pure alcohol. That is the amount in a 341-millilitre bottle of beer or cider at 5 percent alcohol, a 142-millilitre glass of wine at 12 percent, or a 43-millilitre shot of spirits at 40 percent (Paradis et al., 2023). A large glass of wine or a strong craft beer can contain two standard drinks or more.

You can check the arithmetic: 341 millilitres multiplied by 0.05 gives 17.05 millilitres of alcohol. Lesson 4 builds a standard drink calculator for common Canadian beverages.

Case 1.2: Canada moves the boundary of lower-risk drinking (2011 to 2023)

Canada’s Low-Risk Alcohol Drinking Guidelines, released in November 2011, advised people who drink to limit long-term health risk by having no more than 10 standard drinks a week for women and no more than 15 for men, and to limit short-term risk by having no more than three drinks (women) or four drinks (men) on any single occasion (Paradis et al., 2023).

In January 2023, the Canadian Centre on Substance Use and Addiction (CCSA) released Canada’s Guidance on Alcohol and Health, which replaced the 2011 guidelines. It describes a continuum of risk from weekly drinking: risk is low at 2 standard drinks or fewer per week, moderate at 3 to 6, and increasingly high at 7 or more, with each additional drink adding risk. It also states that more than 2 standard drinks on one occasion increases the risk of harm to self and others, including injuries and violence (Canadian Centre on Substance Use and Addiction, 2023; Paradis et al., 2023).

The change came from new evidence on alcohol and disease, especially cancer, and from an explicit choice of risk threshold. The final report explains that advice about voluntary activities generally uses a low risk level of about 1 in 1,000 for premature death, while alcohol guidelines have often used a moderate level of 1 in 100. The 2023 continuum puts “low” at the first threshold and “moderate” up to the second (Paradis et al., 2023). The boundary of lower-risk drinking therefore depends on two things: what the evidence shows, and how much risk experts judge people should be told is acceptable.

Equation 1.1 gives the calculation that places a weekly drinking pattern on the 2023 continuum. It multiplies the number of standard drinks on each drinking day by the number of drinking days in a week.

Weekly standard drinks
W = d × kEq 1.1
the weekly number of standard drinks equals the standard drinks on each drinking day multiplied by the number of drinking days per week.

Worked example. Suppose a hypothetical pattern of 2 standard drinks on each of 3 evenings a week. The weekly total is W = 2 × 3 = 6 standard drinks, which falls in the 2023 Guidance’s moderate-risk range of 3 to 6. Each occasion stays at the 2-drink level that the Guidance links to increased acute risk when exceeded. The same weekly total would have been well within the 2011 limits of 10 drinks for women and 15 for men. The same pattern therefore moved from within the earlier limits to the moderate-risk range because the guideline changed. Use Calculator 1.1 to try other patterns, and notice how the band changes when the same weekly total is concentrated on fewer days.

Cannabis has its own guidelines. Canada’s Lower-Risk Cannabis Use Guidelines, published by Fischer and colleagues in 2017 and updated in 2022, conclude that people can substantially reduce their risk of harm if they delay starting cannabis use until after adolescence, avoid high-potency products and frequent or intensive use, and avoid smoking as a route of use. They also advise using legal, regulated products where possible (Fischer et al., 2017; Fischer et al., 2022). Lesson 7 examines the evidence behind these recommendations. The next subsection turns to the patterns that place use at the higher-risk stage.

5.2 Higher-Risk Use

Higher-risk use is defined by its consequences: use that “has a harmful and negative impact” on the person or on others. Health Canada’s examples show that risk comes from at least three sources. The first is amount and frequency, as in binge drinking or steadily increasing use. The Guidance on Alcohol and Health notes that binge drinking is usually defined as five or more standard drinks in one setting for men, or four or more for women (Paradis et al., 2023). The second is context, as in impaired driving, where a modest dose becomes dangerous because of the activity that follows it. The third is combination. Using two or more substances together can multiply their effects, and Lesson 4 explains why combining depressants is especially dangerous for breathing.

Combining substances is common. The Canadian Substance Use Survey defines polysubstance use as using two or more substances at the same time or on the same occasion. In 2025, 19 percent of people aged 15 and older (about 6.6 million people) reported it in the past year, and the most common combination was alcohol with cannabis, reported by 16 percent (Health Canada, 2026).

Health Canada lists “illegal drug use” as an example of higher-risk use. There is a health reason for this. A substance bought in the unregulated market has no label and no quality control, so the person using it cannot know its content or strength. Lesson 5 shows how this unpredictability has made the unregulated opioid supply in Canada toxic. The example also mixes two kinds of criteria, since legal status is a policy category and risk is a health category. Under this example, a pattern of occasional psilocybin use counts as higher-risk because the substance is illegal, while drinking six standard drinks a week counts as moderate risk under the alcohol continuum. Applying the spectrum well means asking which feature of a pattern creates the risk: the substance, the amount, the setting, the combination or the unregulated supply.

Higher-risk use therefore depends on amount, context, combination and supply. The far end of the spectrum is reached when use becomes a clinical disorder.

5.3 Substance Use Disorder

Health Canada describes addiction, or substance use disorder, as “a treatable medical condition that affects the brain”, involving compulsive, continuous use despite negative impacts (Health Canada, 2022a). The CCSA describes a substance use disorder as a health condition that is diagnosed when a person’s substance use leads to health issues or problems at home, school or work, and notes that it can be mild, moderate or severe; it describes addiction as characteristic of severe substance use disorder (Canadian Centre on Substance Use and Addiction, 2019).

Clinicians diagnose substance use disorder with criteria such as those in the DSM-5. The criteria describe loss of control over use, craving, continued use despite harm to health, relationships or responsibilities, giving up other activities, use in risky situations, tolerance and withdrawal. A diagnosis requires at least 2 of the 11 criteria within the same 12-month period. Severity is mild with 2 or 3 criteria, moderate with 4 or 5, and severe with 6 or more. In moving from DSM-IV to DSM-5, the American Psychiatric Association removed legal problems as a criterion and added craving (NIAAA, 2021; Hasin et al., 2013). As of October 2026, the current version is the DSM-5 text revision (DSM-5-TR), published in 2022, which keeps the term substance use disorder. Lesson 8 explains why tolerance and withdrawal on their own describe physical dependence, which differs from addiction, and Lesson 9 examines the debate over calling addiction a brain disease.

Canadian survey data from 2025 suggest that most people who use substances are far from the disorder end of the spectrum. In 2025, the Canadian Substance Use Survey asked people who had used a substance in the past three months the questions of the World Health Organization’s Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). An estimated 907,000 people, or 4 percent of those who had used any substance in the past three months, were at high risk of dependence, and 4 percent of the population (1.4 million people) reported a need for professional help related to their substance use. Health Canada notes that a screening test cannot diagnose a disorder and that the true number at high risk is likely higher, because people whose use is episodic may not have used in the previous three months (Health Canada, 2026). Globally, the United Nations Office on Drugs and Crime (UNODC) estimated that 64 million people had drug use disorders in 2023, compared with 316 million people who had used a drug other than alcohol or tobacco in the past year (UNODC, 2025). Section 3 examines these surveys in more detail.

5.4 Strengths and Limits of the Spectrum

A spectrum is a model, and like any model it simplifies. The four items that follow summarize what Health Canada’s spectrum adds and where its limits lie.

It describes movement over timev

The spectrum treats stages as states a person passes through, in either direction. This fits research, which Lesson 9 examines, in which many people reduce or stop their use without treatment; a 2019 systematic review, for example, found that remission from alcohol problems without treatment is common, although estimates vary widely with how studies define problems, remission and treatment (Mellor et al., 2019). The spectrum also supports the view that a recurrence of use after a period of recovery is part of the course of a health condition.

It includes harm to others and contextv

By defining lower-risk and higher-risk use partly through effects on family, friends and others, the spectrum captures harms such as impaired driving that a focus on the individual’s health would miss.

It mixes legal and health criteriav

Listing illegal drug use as higher-risk use places some patterns on the spectrum according to the law. The health reason (an unregulated, unpredictable supply) is real, but a careful reader separates the risk created by the substance and pattern from the risk created by its legal status.

It focuses on individual patternsv

The spectrum describes what an individual does. It says little about why some people move toward higher-risk use and others do not, or about the poverty, trauma, housing and policy conditions that shape those movements. Lessons 9 and 10 take up those questions.

Interactive 1.2 asks you to place ten patterns of use on the spectrum. The patterns are hypothetical descriptions of behaviour, written to test the definitions in Table 1.3; several require you to decide which feature of the pattern creates the risk.

Interactive 1.2
Place patterns of use on Health Canada’s spectrum
For each hypothetical pattern, choose the stage that fits best using Health Canada’s descriptions and the 2023 alcohol Guidance. Then select “Check my placements”. The feedback explains the reasoning and notes where reasonable people might disagree.

Summary

This section replaced the old division between use and “abuse” with Health Canada’s five-stage spectrum: non-use, beneficial use, lower-risk use, higher-risk use and substance use disorder. It showed that the boundary of lower-risk use is drawn by guidelines that combine evidence with judgements about acceptable risk, as the move from Canada’s 2011 drinking guidelines to the 2023 Guidance demonstrates. It described higher-risk use through amount, context, combination and supply, and defined substance use disorder with the DSM-5 criteria and severity levels. The spectrum describes individual patterns. Section 3 turns to populations and asks how many people in Canada and the world use each substance, how we know, and who the surveys miss.

Key Takeaways

  • 4.1 For much of the twentieth century, use was divided into acceptable use and “abuse”, and DSM-IV separated substance abuse from substance dependence. Health Canada’s 2022 spectrum instead arranges patterns from non-use through beneficial, lower-risk and higher-risk use to substance use disorder, with varying benefits and harms. People can move back and forth between stages over time and can sit at different stages for different substances.
  • 4.2 Non-use is common and not fixed: in 2025 about one person in six in Canada had used none of the substances the survey asked about. Beneficial use has positive health, social or spiritual effects, such as taking a medication as prescribed or the ceremonial use of traditional tobacco, although a prescribed medicine can still cause side effects or dependence.
  • 5.1 Lower-risk use is defined by guidelines that combine evidence with a judgement about acceptable risk. Canada’s 2011 guidelines set limits of 10 standard drinks a week for women and 15 for men, while the 2023 Guidance rates 2 or fewer as low risk, 3 to 6 as moderate and 7 or more as increasingly high, using a 1 in 1,000 risk threshold for “low”. Weekly standard drinks equal the drinks on each drinking day multiplied by the drinking days per week (Equation 1.1), and a Canadian standard drink holds 13.45 grams of pure alcohol.
  • 5.2 Higher-risk use has a harmful impact on the person or on others, and its risk comes from amount and frequency, context, combination and supply; in 2025, 19 percent of people aged 15 and older reported polysubstance use. Health Canada lists illegal drug use as higher-risk because unregulated drugs have unknown content and strength, an example that mixes a legal category with a health one.
  • 5.3 The DSM-5 diagnoses substance use disorder when at least 2 of 11 criteria occur within 12 months, with severity rated mild (2 or 3 criteria), moderate (4 or 5) or severe (6 or more); it removed legal problems as a criterion and added craving. Canadian survey data from 2025 suggest that most people who use substances do not meet this definition: 4 percent of people who had used a substance in the past three months screened at high risk of dependence.
  • 5.4 The spectrum describes movement over time and counts harms to others and context, but it mixes legal and health criteria and focuses on individual patterns rather than the conditions that shape them. Placing a pattern on it well means asking which feature creates the risk: the substance, the amount, the setting, the combination or the unregulated supply.

Reflection

In November 2011, Canada’s Low-Risk Alcohol Drinking Guidelines advised people who drink to have no more than 10 standard drinks a week (women) or 15 (men). In January 2023, Canada’s Guidance on Alcohol and Health replaced them with a continuum of risk: low at 2 or fewer standard drinks a week, moderate at 3 to 6, and increasingly high at 7 or more, with more than 2 drinks on one occasion linked to a higher risk of injuries and violence. The final report explains that advice on voluntary risks usually treats a 1 in 1,000 lifetime risk of premature death as low, while alcohol guidelines have often used 1 in 100. Health Canada’s 2022 spectrum defines lower-risk use as use within such guidelines and lists illegal drug use as an example of higher-risk use. In 150 to 250 words, (a) explain how a hypothetical pattern of 2 standard drinks on each of 4 evenings a week is classified under each document, (b) explain what the change shows about how the boundary of lower-risk use is drawn, and (c) identify one limitation of the spectrum.

Model answer

(a) The pattern gives 2 × 4 = 8 standard drinks a week. Under the 2011 guidelines, 8 is below both the 10-drink limit for women and the 15-drink limit for men, so it would have counted as low-risk drinking. Under the 2023 Guidance, 8 is in the increasingly high risk band of 7 or more drinks a week, even though no single evening goes above 2 drinks.

(b) The same pattern moved from low risk to increasingly high risk because the line moved. The boundary of lower-risk use depends on the evidence available, which by 2023 showed stronger links between alcohol and cancer, and on a judgement about how much risk people should be told is acceptable. Choosing 1 in 1,000 for low risk, the level used for other voluntary risks, moved the line well below where a 1 in 100 standard would put it. A spectrum therefore combines science with values.

(c) One limitation is that the spectrum mixes legal and health criteria. Listing illegal drug use as higher-risk use places some patterns by their legal status. There is a real health reason, because unregulated drugs have unknown content, but an occasional, low-dose pattern of an illegal substance and a heavy drinking pattern are then judged on different grounds, which a careful reader should keep separate.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: Which list gives the five stages of Health Canada’s 2022 substance use spectrum in order?

Health Canada’s infographic, published in May 2022, runs from non-use through beneficial, lower-risk and higher-risk use to addiction (substance use disorder). The list using misuse and abuse reflects older language that the lesson explains has fallen out of favour.

Question 2: Under Canada’s Guidance on Alcohol and Health (2023), how is a pattern of 2 standard drinks on each of 4 evenings a week classified?

Equation 1.1 gives 2 × 4 = 8 standard drinks a week, and the 2023 continuum places 7 or more in the increasingly high risk band. Keeping each occasion at 2 drinks avoids the per-occasion warning but does not change the weekly band, and the 2011 limits were replaced in 2023.

Question 3: What change did the DSM-5 (2013) make to the diagnosis of substance-related problems?

DSM-5 combined DSM-IV’s separate abuse and dependence diagnoses into substance use disorder, diagnosed with 2 or more of 11 criteria in 12 months and rated mild, moderate or severe. It removed legal problems and added craving, the reverse of the first distractor, and 6 or more criteria marks severe disorder, while the threshold for any diagnosis is 2.

Question 4: Why does Health Canada’s spectrum list illegal drug use as higher-risk use, and what is the main critique of that example?

The health reason is that a drug from the unregulated market has no label or quality control. The lesson notes that the example also places a pattern on the spectrum by its legal status, which is a policy category. Addictiveness varies widely within both legal and illegal substances, so the first distractor is false.
Section 3 of 5

Patterns of Use in Canada and the World, and Who the Surveys Miss

⏱ Estimated reading time: 40 minutes
Section 3 of 5

Patterns of Use

Canadian and global survey data, and the people the surveys miss.

Reading surveys

Four terms to read any survey

Prevalence

The share reporting a behaviour in a stated period.

Time window

Lifetime, past year or past 30 days.

Weighting

Makes the sample resemble the population.

Confidence interval

Uncertainty from sampling, and nothing more.

Canada, 2025

Past-year use, people aged 15 and older

77%alcohol
32%cannabis
10%any illegal or other substance of concern

Canadian Substance Use Survey, 2025 (Health Canada, 2026).

Age and counts

From a percentage to a number of people

Estimated number of people (Eq 1.2)
\[ N = p \times P = 0.325 \times 34.9\ \text{million} \approx 11.3\ \text{million} \]

Past-year cannabis use, 2025: 50.4% at ages 18 to 24; 16.8% at 65 and older.

World, 2023

The World Drug Report 2025

316Mpeople used a drug in the past year
244Mused cannabis
1 in 12people with drug use disorders received treatment
Who is missing

The people surveys miss

The territories
Prisons and other institutions
First Nations reserves
People without stable housing or a phone
Young people out of school
Rare, stigmatized behaviours

57,509 apparent opioid toxicity deaths in Canada, January 2016 to March 2026 (Public Health Agency of Canada).

Carry forward

From numbers to words

  • In 2025, alcohol and cannabis were the substances most used in Canada.
  • Use of cannabis and illegal drugs peaked among young adults.
  • Survey gaps fall where harms concentrate, so other data sources are needed.
  • Section 4 examines how language shapes stigma and policy.

Introduction

Claims about drug use travel quickly, for example that “everyone” vapes or that a new drug is sweeping the country. Testing such claims requires counts, and counting substance use is difficult because people use substances privately, some use is illegal, and the people at highest risk of harm are often the hardest to reach.

This section explains how Canada and international agencies measure substance use, what Canadian surveys from 2023 to 2025 and a global report from 2025 showed, and where they fall short. It draws on the Canadian Substance Use Survey for the general population, the Canadian Student Alcohol and Drugs Survey for students, and the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2025 for global estimates. HSCI 402 develops surveillance and the measurement of burden; the aim here is to read survey results accurately and to recognize who they leave out.

Learning Objectives

  • 6.1 Define prevalence and distinguish lifetime, past-year and past-30-day use, and explain at an introductory level what weighting and a confidence interval add to a survey estimate.
  • 6.2 Describe Canada’s main substance use surveys, including the population each covers and how it collects data.
  • 6.3 Describe the main patterns of past-year substance use in Canada by substance and age group, using the Canadian Substance Use Survey (2023 and 2025) and the Canadian Student Alcohol and Drugs Survey (2023 to 2024).
  • 6.4 Convert a survey percentage into an estimated number of people.
  • 6.5 Summarize global patterns of drug use reported in the UNODC World Drug Report 2025.
  • 7.1 Identify the groups that household and school surveys miss and explain why they are missed.
  • 7.2 Explain why the gaps matter where harm is concentrated, and name other data sources that can fill them.

Content note

This section refers to deaths from the toxic unregulated drug supply in Canada. Support is available at any time: the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677), and the Hope for Wellness Help Line for Indigenous people across Canada (1-855-242-3310).

6.1 How Surveys Measure Substance Use

Most national figures on substance use come from surveys in which people report their own behaviour. A survey selects a sample of people, asks them questions, and uses their answers to estimate patterns in the whole population. The box that follows defines the terms needed to read the results.

Terms for reading a substance use survey

Prevalence is the share of a population that reports a behaviour during a stated period. If 325 of every 1,000 people report using cannabis in the past 12 months, the past-year prevalence is 32.5 percent.

Time windows change the meaning of a prevalence. Lifetime use means ever used, past-year use means used in the past 12 months, and past-30-day use means used in the past month. Lifetime prevalence is always the highest of the three and says little about current patterns.

Weighting adjusts the answers so that the sample resembles the population. If young men are under-represented among respondents, each of their answers counts for a little more. The 2025 Canadian Substance Use Survey was weighted to population projections by province, age and sex at birth (Health Canada, 2026).

A confidence interval is a range around an estimate that reflects the uncertainty from sampling only some people. A narrow interval means the estimate is precise. It does not protect against people who were never sampled or who answered inaccurately, which 7.1 Who the Surveys Miss discusses.

6.2 Canada’s Substance Use Surveys

Canada runs several surveys that ask about substance use. Table 1.4 compares the four that this course uses most. Each has a different target population, and each excludes some groups by design.

Table 1.4. Canadian surveys that measure substance use, with their populations, methods and most recent cycles as of October 2026 (Health Canada, 2024; Health Canada, 2025b; Health Canada, 2026; Statistics Canada, 2025).

SurveyPopulationMethodRecent cycle
Canadian Substance Use Survey (CSUS), Health Canada; called the Canadian Alcohol and Drugs Survey before 2023People aged 15 and older in the ten provincesRecruitment by telephone (mostly cell phones), with an online questionnaire; run every two years2025: 36,061 respondents, collected from 7 January 2025 to 5 January 2026, weighted to represent 34.9 million people
Canadian Student Alcohol and Drugs Survey (CSADS), Health Canada; called the Canadian Student Tobacco, Alcohol and Drugs Survey from 2014 to 2022Students in grades 7 to 12Questionnaires completed in randomly selected schools2023 to 2024: 51,844 students in nine provinces; Quebec did not take part
Canadian Postsecondary Education Alcohol and Drug Use Survey (CPADS), Health CanadaStudents at colleges and universitiesSurvey of postsecondary studentsResults on Health Infobase
Canadian Community Health Survey (CCHS), Statistics CanadaPeople aged 18 and older in the provinces and territories (2025)General health survey answered online, by telephone or in person2025 cycle

The CSUS changed its methods in 2023, and Health Canada recommends against comparing the 2023 results with earlier cycles. Between 2023 and 2025 the questionnaire changed again, for example by separating substances that had been grouped and by adding plain-language text, so some differences between the two cycles may reflect better measurement of the same behaviour (Health Canada, 2024; Health Canada, 2026). This caution applies to every comparison in 6.3 Patterns of Use in Canada.

6.3 Patterns of Use in Canada

The 2025 CSUS found that 84 percent of people aged 15 and older had used at least one substance in the past year. Alcohol remained the most common (77 percent, about 26.9 million people), followed by cannabis, prescription opioids and cigarettes. For 37 percent of people, alcohol was the only substance they used (Health Canada, 2026). Figure 1.3 compares past-year use of the main substances in 2023 and 2025.

2023 2025 0 20 40 60 80 100 Percent reporting use in the past 12 months Alcohol 79 77 Cannabis 32 32 Prescription opioids 10 15 Prescription sedatives 13 11 Prescription stimulants 5 8 Any illegal or other substance* 8 10 Psychedelics 6 7 Cocaine 3 3 MDMA or similar 2 2
Figure 1.3. Percentage of people aged 15 and older in Canada who reported using each substance in the past 12 months, Canadian Substance Use Survey, 2023 and 2025. Data from Health Canada (2026), Figures 1 and 2. Increases for prescription opioids, prescription stimulants, psychedelics and any illegal or other substance should be interpreted with caution because the questions changed in 2025. *The 2025 measure of any illegal or other substance of concern added substances that were not asked about in 2023. Health Canada’s summary of the 2023 results (Health Canada, 2024) reported 13 percent for opioid use in 2023; the 2025 report and the current data tool give 10 percent for prescription opioids in 2023, and this lesson uses the current figures.

Figure 1.3 shows that in both cycles alcohol and cannabis were used by far more people than any illegal drug. In 2025, most prescription medicine use came through the medical system: among people who used prescription opioids in 2025, 90 percent obtained all of them from the medical system, as did 89 percent of people who used prescription sedatives and 82 percent of people who used prescription stimulants. Among illegal drugs, psychedelics were the most common (7 percent, about 2.6 million people), and psilocybin was the most commonly used psychedelic (Health Canada, 2026).

Patterns differ sharply by age. In 2025, youth and young adults aged 15 to 24 were more likely than adults aged 25 to 54 to have used cannabis, vapes and prescription stimulants, and less likely to have used alcohol and prescription opioids (Health Canada, 2026). Among middle and secondary school students, the Canadian Student Alcohol and Drugs Survey for 2023 to 2024 found that 37 percent had drunk alcohol and 18 percent had used cannabis in the past year, 7 percent had used an illegal drug, and 15 percent had vaped a non-cannabis product in the past 30 days (Health Canada, 2025b). Table 1.5 shows past-year use by age group in the 2025 CSUS.

Table 1.5. Percentage of people in each age group who reported using selected substances in the past 12 months, Canadian Substance Use Survey, 2025. Data from the Health Infobase data tool (Health Canada, 2026).

Age groupAlcoholCannabisAny illegal or other substancePsychedelicsCocaine or crackPharmaceutical stimulants
15 to 1749.629.010.98.11.817.1
18 to 2476.750.417.113.14.318.3
25 to 3478.144.317.612.85.513.7
35 to 4477.938.114.210.64.510.0
45 to 5478.631.69.06.42.16.2
55 to 6479.724.75.13.81.12.8
65 and older78.116.82.01.10.40.9
All ages 15+77.132.510.17.42.88.2

Table 1.5 shows that in 2025 alcohol use was similar across adult age groups, while cannabis and illegal drug use peaked among people aged 18 to 34 and declined with age. Pharmaceutical stimulant use was highest among people under 25. The 15 to 17 age group reported lower use of alcohol and cannabis than young adults.

Interactive 1.3 lets you explore the same data for ten substances, both survey cycles and two breakdowns: age group, and experience of housing insecurity or homelessness. Each bar shows the estimate and its 95 percent confidence interval.

Interactive 1.3
Explore past-year substance use in the Canadian Substance Use Survey
Choose a substance, a survey cycle and a breakdown. The bars show the weighted percentage of people aged 15 and older who reported use in the past 12 months, and the thin line on each bar shows the 95 percent confidence interval. Data are from Health Canada’s Health Infobase data tool (updated June 2026). Health Canada advises caution when comparing 2023 and 2025 because some questions changed.
Try it 1.1: A guided reading of a Canadian Substance Use Survey table

Open Health Canada’s data tool, Drug and alcohol use in Canada: General population, on Health Infobase. Select the topic Cannabis, the indicator Using cannabis, the timeframe Past 12 months and the breakdown Age, then open the “Text description” table under the chart.

  1. Find the past-year prevalence of cannabis use for people aged 18 to 24 in the most recent cycle, with its confidence interval. Check it against Table 1.5 or Interactive 1.3.
  2. Find the age group with the lowest prevalence and the one with the highest. Repeat the steps for the topic Alcohol and describe how the age pattern differs from cannabis.
  3. Read the technical notes and the survey description. List every group of people who could not have been included in the sample, and every group you think is likely to be under-represented.
  4. Write one sentence that reports your cannabis result accurately, naming the survey, the year, the age group and the time window.

A model sentence for step 4: “In the 2025 Canadian Substance Use Survey, 50.4 percent of people aged 18 to 24 in the ten provinces reported using cannabis in the past 12 months.” 7.1 Who the Surveys Miss discusses the groups you listed in step 3.

6.4 From a Percentage to a Number of People

Surveys report percentages, while planners often need numbers of people. Equation 1.2 converts one into the other by multiplying the prevalence, written as a proportion, by the size of the population the survey represents.

Estimated number of people
N = p × PEq 1.2
the estimated number of people equals the prevalence, written as a proportion multiplied by the population the survey represents.

Worked example. In 2025, the CSUS estimated past-year cannabis prevalence at 32.5 percent, with a 95 percent confidence interval from 31.8 to 33.1 percent, in a population of 34.9 million people aged 15 and older. The estimate is N = 0.325 × 34.9 million = 11.3 million people. Applying the same formula to the ends of the confidence interval gives a range from 0.318 × 34.9 = 11.1 million to 0.331 × 34.9 = 11.6 million. Health Canada reports the same figure of 11.3 million (Health Canada, 2026). Calculator 1.2 applies the formula to any estimate.

Canadian patterns of use look different when they are placed in a global context.

6.5 Global Patterns of Drug Use

The UNODC publishes the World Drug Report each year, drawing on national surveys, treatment data, drug seizures and other information reported by governments. Its estimates cover substances controlled under the international drug conventions, so they exclude alcohol and tobacco. The 2025 report estimated that 316 million people, or 6 percent of the world’s population aged 15 to 64, had used a drug in the past year in 2023. That is an increase from 246 million people (5.2 percent) in 2013, which UNODC attributes partly to population growth and partly to a real rise in prevalence and the availability of better data (UNODC, 2025). Table 1.6 gives the estimates by drug.

Table 1.6. Estimated number of people worldwide aged 15 to 64 who used each drug in the past year, and the corresponding prevalence, 2023 (UNODC, 2025).

DrugPeople who used it in the past yearPrevalence among people aged 15 to 64
Any drug (excluding alcohol and tobacco)316 million6.0 percent
Cannabis244 million4.6 percent
Opioids (synthetic opioids and natural opiates)61 million1.2 percent
Amphetamines31 million0.6 percent
Cocaine25 million0.5 percent
“Ecstasy”21 million0.4 percent

The report describes several patterns that connect to later lessons. The use of most drugs was higher in North America than in other subregions, and North America had both the largest number of people who used cannabis and the highest past-year prevalence of cannabis use. Cannabis use was far more common among men (7.0 percent) than women (2.3 percent). Cocaine was the fastest-growing illicit drug market, with use rising sharply since 2017. Of the estimated 64 million people with drug use disorders in 2023, only 1 in 12 received any drug-related treatment, and among women the figure was 1 in 18 (UNODC, 2025).

Global figures carry larger uncertainties than Canadian ones, because many countries have no recent national survey. The report itself notes that wastewater analysis suggests the use of “ecstasy”-type substances in South-Eastern Europe could be higher than population surveys show (UNODC, 2025). That observation leads to the central question of the rest of this section: who and what do surveys miss?

7.1 Who the Surveys Miss

Every survey has a sampling frame, the list or method from which participants are drawn. People outside the frame cannot be selected, and people inside it may decline or may not answer honestly. For substance use, the gaps tend to fall on groups whose use and harms are among the highest. The six items that follow describe the main gaps in Canadian household and school surveys.

People outside the geographic or age framev

In 2025, the CSUS covered people aged 15 and older in the ten provinces, so the territories and younger adolescents were outside its frame. The student survey of 2023 to 2024 covered nine provinces because Quebec did not take part (Health Canada, 2025b), and earlier cycles of the student survey excluded residents of Yukon, Nunavut and the Northwest Territories (University of Waterloo, 2023).

People living in institutionsv

In 2025, Statistics Canada’s Canadian Community Health Survey excluded the institutionalized population, meaning people who live in institutions such as prisons or long-term care facilities (Statistics Canada, 2025). The student survey also excluded residents of institutions. People in custody are of particular interest because, as Lesson 5 shows, the period after release from prison carries a high risk of drug-related death.

First Nations communitiesv

In 2025, the Canadian Community Health Survey excluded people living on reserves and other Aboriginal settlements in the provinces, and the student survey excluded schools on First Nations reserves (Statistics Canada, 2025; University of Waterloo, 2023). These exclusions reflect survey logistics and jurisdiction. They also mean that national averages say little about First Nations communities, whose own organizations, such as the First Nations Health Authority in British Columbia, produce and govern data about their members. Lesson 10 discusses these data.

People without stable housing or a telephonev

A survey that recruits by telephone and asks people to complete an online questionnaire can reach only people with a working phone and internet access. The CSUS did reach some people with recent experience of housing insecurity or homelessness: in 2025, 1,304 respondents reported it in the past year, and 20.5 percent of them reported using an illegal or other substance of concern, compared with 8.8 percent of people with no lifetime experience of housing insecurity (Health Canada, 2026). People living on the street without a phone are much less likely to be reached, so their use is probably under-represented. That last point is an inference from the survey design, which the technical notes do not quantify.

Young people who are not in schoolv

A school survey can only include students who are enrolled and present on the survey day. Young people who have left school, are frequently absent or attend special schools are under-represented or excluded; earlier cycles of the student survey excluded special-needs schools, schools on military bases and very small schools (University of Waterloo, 2023).

Non-response, under-reporting and rare behavioursv

People can decline to take part. Because the CSUS recruits through random telephone numbers, there is no list of non-respondents, and the results cannot be adjusted for non-response, which can make confidence intervals look narrower than they should (Health Canada, 2026). People may also under-report illegal or stigmatized behaviour; Health Canada revised the 2025 questionnaire partly to reduce stigma. Finally, rare behaviours produce few responses. In 2025, heroin use was reported by 45 of about 36,000 respondents (0.1 percent), and nitazene use was below 0.05 percent, so these estimates are imprecise.

7.2 Why the Gaps Matter: Use and Harm in Different Places

The gaps matter most where harm is concentrated. In the 2025 CSUS, heroin, non-prescribed fentanyl and nitazenes each appear as a fraction of 1 percent of the population. Yet the Public Health Agency of Canada reported 57,509 apparent opioid toxicity deaths in Canada between January 2016 and March 2026, and noted that accidental poisonings were the leading cause of death in 2024 for males aged 20 to 49 and females aged 20 to 39 (Public Health Agency of Canada, 2026). In British Columbia, the BC Coroners Service reported 1,826 deaths from unregulated drug toxicity in 2025, a preliminary figure about 21 percent lower than the 2,315 deaths of 2024, and 69 percent of the people who died in 2025 were aged 30 to 59 (BC Coroners Service, 2026a). A household survey that estimates 0.1 percent heroin use cannot describe the population in which these deaths occur, because many of the people at highest risk are outside its frame or are too few in the sample to measure. Lesson 5 and HSCI 402 examine who dies and why.

Figure 1.4 summarizes four kinds of data that, taken together, give a fuller picture than any survey alone.

Population surveys Show: who uses which substances, how often, by age and other groups Miss: people outside the frame, non-response and under-reporting Surveillance of harms Show: hospital visits, poisonings and deaths, with toxicology Miss: the much larger number of people who use without severe harm Drug checking Shows: what samples of drugs actually contain, and how this changes Misses: who uses them and how much, beyond the samples tested Wastewater analysis Shows: total use of some drugs in a community, without self-report Misses: who uses, how many people, and the patterns of individual use
Figure 1.4. Four kinds of data on substance use and what each shows and misses. Surveys describe use across the population, surveillance describes serious harms, drug checking describes the supply, and wastewater analysis measures community-level use. HSCI 402 develops surveillance and drug checking.

Two further sources come from communities themselves. Indigenous-governed organizations collect and interpret data about their own members, and organizations of people who use drugs, such as the Vancouver Area Network of Drug Users (VANDU), which describes itself as a grassroots organization with more than 3,000 members, bring the knowledge of people whom surveys often miss. Section 4 returns to VANDU when it discusses the language that groups choose for themselves.

Summary

This section explained how surveys estimate prevalence and how weighting and confidence intervals qualify those estimates. In Canada in 2025, alcohol and cannabis were the substances most used, and cannabis and illegal drug use peaked among people aged 18 to 34; globally, 316 million people used a drug other than alcohol or tobacco in 2023. Canadian surveys have missed people in the territories, in institutions, on reserves, without stable housing or out of school, and they have struggled with rare and stigmatized behaviours, which is why harm surveillance, drug checking, wastewater analysis and community-governed data are needed alongside them. Stigma affects measurement as well as people. Section 4 examines how language creates and reduces stigma, and how words shape drug policy.

Key Takeaways

  • 6.1 Prevalence is the share of a population that reports a behaviour during a stated period, and lifetime, past-year and past-30-day windows give different figures, with lifetime prevalence always the highest. Weighting makes the sample resemble the population, and a confidence interval reflects sampling uncertainty only, not people who were never sampled or who answered inaccurately.
  • 6.2 In 2025, the Canadian Substance Use Survey covered people aged 15 and older in the ten provinces, recruited by telephone and answering online; the Canadian Student Alcohol and Drugs Survey covers students in grades 7 to 12; CPADS covers postsecondary students; and the CCHS is a general health survey. Each has excluded some groups by design, and changes in methods in 2023 and 2025 mean comparisons across cycles need caution.
  • 6.3 In 2025, 84 percent of people aged 15 and older in Canada used at least one substance in the past year, and alcohol (77 percent) and cannabis (32 percent) far exceeded any illegal drug; most prescription medicine use came through the medical system. In 2025, cannabis and illegal drug use peaked among people aged 18 to 34 and declined with age, while alcohol use was similar across adult age groups.
  • 6.4 An estimated number of people equals the prevalence, written as a proportion, multiplied by the population the survey represents (Equation 1.2). The 2025 past-year cannabis prevalence of 32.5 percent in a population of 34.9 million gives about 11.3 million people, and applying the formula to the ends of the confidence interval gives a range.
  • 6.5 The UNODC estimated that 316 million people, 6 percent of people aged 15 to 64, used a drug other than alcohol or tobacco in 2023, with cannabis used by 244 million. Of the 64 million people with drug use disorders, only 1 in 12 received any drug-related treatment, and global figures carry larger uncertainties than Canadian ones.
  • 7.1 Canadian household and school surveys have missed people in the territories or outside the age frame, people in institutions, First Nations communities on reserve, people without stable housing or a telephone and young people who are not in school. Non-response, under-reporting and rare behaviours add further error, and random telephone recruitment means the CSUS cannot be adjusted for non-response.
  • 7.2 The gaps matter most where harm is concentrated: the 2025 CSUS estimated heroin use at 0.1 percent, yet the Public Health Agency of Canada reported 57,509 apparent opioid toxicity deaths between January 2016 and March 2026. Harm surveillance, drug checking, wastewater analysis, Indigenous-governed data and organizations of people who use drugs such as VANDU describe what surveys miss.

Reflection

The 2025 Canadian Substance Use Survey recruited 36,061 people aged 15 and older in the ten provinces by telephone and asked them to complete an online questionnaire. It estimated that 0.1 percent had used heroin in the past year and fewer than 0.05 percent had used nitazenes. The BC Coroners Service reported 1,826 deaths from unregulated drug toxicity in British Columbia in 2025 (a preliminary figure), and the Public Health Agency of Canada reported 57,509 apparent opioid toxicity deaths in Canada between January 2016 and March 2026. In 2025, Statistics Canada’s Canadian Community Health Survey excluded people living on reserves, full-time members of the Canadian Forces and the institutionalized population, and earlier cycles of the national student survey excluded schools on First Nations reserves and special-needs schools. In 150 to 250 words, explain why a household survey can show very low use of these drugs while deaths remain high, name three groups that household and school surveys miss, and propose one other data source that could help for each group.

Model answer

A household survey estimates use among the people it can reach, and the people at highest risk of dying from the toxic supply are often the ones it cannot reach or cannot count precisely. A telephone and online survey needs a working phone and internet access. It excludes the territories, it is very unlikely to reach people in prisons, and a behaviour reported by 45 of 36,000 respondents produces an imprecise estimate. People may also under-report illegal use. A figure of 0.1 percent for heroin therefore tells us little about the population in which 1,826 British Columbians died in 2025.

Three groups the surveys miss, with other sources:

  • People released from or living in prisons. Institutional populations are excluded. Correctional health records and coroners’ data on deaths after release would help.
  • People who are unhoused without a phone. Community-based research with organizations of people who use drugs, such as VANDU, can reach them, and drug checking shows what they are being sold.
  • First Nations people living on reserve. Surveys and school samples have excluded reserves. Data collected and governed by First Nations organizations, such as the First Nations Health Authority in British Columbia, would be more appropriate.

Combining these sources with surveillance of hospital visits and deaths gives a fuller picture than any survey alone.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: In 2025, the Canadian Substance Use Survey estimated that 32.5 percent of people aged 15 and older used cannabis in the past year, in a population of 34.9 million. About how many people is this?

Equation 1.2 gives 0.325 × 34.9 million = 11.3 million, the figure Health Canada reports. 26.9 million is the number who drank alcohol (77 percent), and 1,134 million comes from multiplying 32.5 by 34.9 without first converting the percentage to a proportion.

Question 2: Which group lies outside the sampling frame of the Canadian Substance Use Survey by design?

The survey covers people aged 15 and older in the ten provinces, so the territories are outside its frame. People with recent housing insecurity are a tempting answer, but 1,304 such respondents took part in 2025; the concern is that people without a phone or stable housing are under-represented.

Question 3: Which statement about global drug use in 2023 matches the UNODC World Drug Report 2025?

UNODC estimated 316 million people (6 percent of people aged 15 to 64) used a drug in 2023, with cannabis used by 244 million. The 64 million figure is the number with drug use disorders, of whom 1 in 12 received treatment, and prevalence rose from 5.2 to 6.0 percent.

Question 4: Why can the Canadian Substance Use Survey estimate heroin use at 0.1 percent while the Public Health Agency of Canada reports 57,509 apparent opioid toxicity deaths between 2016 and early 2026?

Household surveys miss people in institutions, without stable housing or phones, and in the territories, and rare behaviours yield few respondents. The deaths were opioid toxicity deaths, mostly among adults, so the alcohol and under-15 options are wrong; the survey does publish opioid estimates.
Section 4 of 5

Language, Stigma and Drug Policy

⏱ Estimated reading time: 35 minutes
Section 4 of 5

Language, Stigma and Drug Policy

Person-first terms, experimental evidence, and how words shape policy.

Health Canada, 2022

Three levels of stigma

Self

Internalized shame that stops a person seeking help.

Social

Negative attitudes and behaviour from others.

Structural

Policies and laws that raise barriers to help.

A scoping review of reviews concluded that stigma among health professionals affects the care of people with substance use disorders (Cazalis et al., 2023).

Person-first language

Terms to avoid, terms to use

Avoid

Addict, junkie, user, abuser; clean or dirty; substance abuse.

Use

People who use drugs; people in recovery; positive or negative test; substance use.

Groups such as VANDU may choose their own names, and respectful practice follows those choices.

Case 1.3

One label, different judgements

“Substance abuser”

More agreement with blame and punishment.

“Has a substance use disorder”

Less agreement with blame and punishment.

A randomized vignette experiment with clinicians in the United States (Kelly & Westerhoff, 2010). A Dutch study that repeated the design with care professionals did not find the same effect (Martinelli et al., 2020).

Weighing the evidence

What the experiments show, and their limits

  • In one study, labels such as “addict” carried strong negative associations (Ashford et al., 2018); in another, stories of successful treatment reduced negative attitudes (McGinty et al., 2015).
  • A narrative review concluded that stigmatizing language may contribute to poorer treatment outcomes (Werder et al., 2022).
  • Vignettes measure judgements of hypothetical people, so effects on real care remain an evolving research question.
Words and policy

Language written into law and data

Problematic substance use should be addressed primarily as a health and social issue.Controlled Drugs and Substances Act, s. 10.1 (2022)
Overdose
Drug toxicity
Poisoning
Bringing it together

Four lenses on one subject

Categories

Pharmacology and law

Spectrum

Patterns of use

Patterns

Surveys and their gaps

Language

Stigma and policy

Next: the reflection below, then the final assessment.

Introduction

The first three sections of this lesson have used a particular vocabulary: “people who use drugs”, “substance use disorder”, “unregulated drug supply”. A reader who has seen news coverage of drugs will have met other words for the same things, some of them insulting. The choice between them is sometimes dismissed as politeness. This section examines studies that test whether word choice changes how people, including clinicians, judge a person who uses substances, what those studies can and cannot show, and how the language of laws and agencies frames drug problems and their solutions.

The section defines stigma, sets out person-first language, examines an influential experiment and the studies that followed it, and traces the influence of language on Canadian drug policy. HSCI 214 develops the theory of stigma, including how it is produced and how it affects health; this section concentrates on language.

Learning Objectives

  • 8.1 Define stigma and distinguish self stigma, social stigma and structural stigma, with an example of each.
  • 8.2 Use person-first and non-stigmatizing terms for people who use substances, and explain why some communities choose other names for themselves.
  • 8.3 Describe the design and findings of Kelly and Westerhoff’s (2010) randomized study of two terms, and evaluate what it and the studies that followed do and do not show.
  • 9.1 Explain how words written into law shape drug policy, using the 2022 declaration of principles in the Controlled Drugs and Substances Act.
  • 9.2 Compare the terms Canadian agencies and campaigns use for drug-related deaths and the policy messages each carries.
  • 9.3 Explain how metaphors and historical language have framed drug policy and how language affects measurement.
  • 10.1 Apply the concepts of the lesson to British Columbia’s 2025 data on unregulated drug toxicity deaths.

Content note

This section discusses language about deaths from the toxic unregulated drug supply. Support is available at any time: the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677), and the Hope for Wellness Help Line for Indigenous people across Canada (1-855-242-3310).

8.1 What Stigma Is

Health Canada defines stigma as “negative attitudes, beliefs or behaviours about or towards a group of people because of their situation in life” (Health Canada, 2022b). The Canadian Centre on Substance Use and Addiction (CCSA) notes that international studies by the World Health Organization found hazardous alcohol and drug use disorders among the most stigmatized conditions, and that stigma is “a significant barrier to well-being and good health for people who use substances” (Canadian Centre on Substance Use and Addiction, 2019).

Health Canada distinguishes three types of stigma, which Figure 1.5 draws as nested circles. Self stigma occurs when a person internalizes negative messages about people who use drugs and applies them to themselves. Social stigma is negative attitudes or behaviour toward people who use drugs or toward their family and friends. Structural stigma is “policies in health and social services that increase stigma and barriers to getting help” (Health Canada, 2022b). The CCSA argues that stigmatizing language discourages people from seeking help and can influence the decisions of elected officials about resources and laws (Canadian Centre on Substance Use and Addiction, 2019). On health care, a 2023 scoping review of earlier reviews found that between 20 and 51 percent of health professionals held negative attitudes or beliefs about substance use disorders, and concluded that this stigma affects the care of people with these disorders (Cazalis et al., 2023).

Structural stigma Laws and service policies that raise barriers to help (example: criminal penalties for personal possession) Social stigma Negative attitudes and behaviour from others (example: labelling someone an “addict”) Self stigma Shame that stops a person from seeking help
Figure 1.5. Three levels of stigma as defined by Health Canada (2022b), with examples drawn from Health Canada, the CCSA (2019) and the Controlled Drugs and Substances Act. Language operates at every level: in what people say to and about one another, in how people describe themselves, and in the wording of laws and policies.

With stigma and its three levels defined, the next question is what language public health agencies recommend in its place.

8.2 Person-First Language

The CCSA defines person-first language as “language that acknowledges someone as a person before describing their personal attributes or health conditions”. It explains that calling someone an “addict” dehumanizes the person and links a health condition to their identity, while “a person is not defined by their illness or health condition” (Canadian Centre on Substance Use and Addiction, 2019). Table 1.7 brings together the terms Health Canada and the CCSA recommend avoiding and the terms they recommend using.

Table 1.7. Terms to avoid and terms to use when writing or speaking about substance use, compiled from Health Canada (2022b), the CCSA (2019) and Ashford, Brown and Curtis (2018).

TopicTerms to avoidTerms to use
People who use drugsAddicts, junkies, users, drug or substance abusers, recreational drug usersPeople who use drugs or substances; people with an addiction or substance use disorder; people with lived or living experience; people who occasionally use drugs
People who have stopped usingFormer drug addict; describing a person as “clean”People who have used drugs; people in recovery; people with lived or living experience
The behaviourDrug or substance abuse; drug or substance misuse; problematic drug useSubstance use; addiction or substance use disorder; drug dependence; higher-risk substance use; substance use harms
Test resultsA “clean” or “dirty” testA negative or positive test result
Returning to useRelapse, when it implies failureRecurrence of use

Two qualifications keep the table in perspective. First, some recommended terms are still debated. “Relapse” remains common in clinical writing, and Ashford, Brown and Curtis (2018) found that both “relapse” and “recurrence of use” carried negative associations, with “recurrence of use” carrying a stronger positive one. Second, the law does not always follow the guidance. Health Canada lists “problematic drug use” among terms to avoid, while the declaration of principles added to the Controlled Drugs and Substances Act in 2022, discussed under 9.1 How Words Written into Law Shape Drug Policy, uses the phrase “problematic substance use”.

Person-first language is the default for writing about other people, and communities sometimes choose different names for themselves. The Vancouver Area Network of Drug Users (VANDU) describes itself as “a group of users and former users who work to improve the lives of people who use drugs” and as a “grassroots democratic organization of drug users” with more than 3,000 members (Vancouver Area Network of Drug Users, n.d.). Its name uses a term that Health Canada lists among words to avoid. The difference reflects who is speaking. A group that names itself is claiming an identity and a political voice, while an outsider who applies the same label to someone else may reduce that person to a behaviour. Respectful practice uses the names that people and groups choose for themselves and uses person-first language when no preference is known.

These are the recommended terms and the reasons for them. Whether the evidence supports the claim that these terms change judgements is the next question.

8.3 Testing Whether Labels Shift Judgements

Arguments about language are easy to make and hard to test. A randomized experiment can test them, because it compares groups that differ only in the words they read. Case 1.3 describes one such experiment, published in 2010, whose design a later study repeated in part.

Case 1.3: “Substance abuser” or “having a substance use disorder”? (Kelly and Westerhoff, 2010)

John F. Kelly and Cassandra Westerhoff, of the Center for Addiction Medicine at Massachusetts General Hospital in Boston, asked whether describing a person as “a substance abuser” or as “having a substance use disorder” evokes different judgements. They recruited clinicians attending two mental health conferences; 516 took part, a response rate of 71 percent. Most were highly trained: 65 percent held doctoral-level degrees, and their mean age was 51.

Each clinician was randomly assigned to read one of two versions of a short vignette about a person with a substance-related problem. The versions were identical except for the term used. Clinicians then rated their agreement with statements grouped into three scales: perpetrator-punishment (whether the person was to blame and should face punitive action), social threat, and victim-treatment (whether the person should receive therapeutic help).

The groups did not differ on the social threat or victim-treatment scales. They did differ on the perpetrator-punishment scale: clinicians who read “substance abuser” agreed more strongly that the person was personally culpable and that punitive measures should be taken. The authors concluded that “even among highly trained mental health professionals”, the two common terms evoke systematically different judgements (Kelly & Westerhoff, 2010).

Figure 1.6 draws the design of the experiment. The randomization is what allows the difference in judgements to be attributed to the term itself.

516 clinicians at two conferences 71 percent response rate Randomized Vignette version A “is a substance abuser” Vignette version B “has a substance use disorder” Same rating scales Perpetrator- punishment Higher agreement with version A: blame and punishment Social threat No difference Victim-treatment No difference
Figure 1.6. The design and results of Kelly and Westerhoff’s (2010) randomized vignette study. Because clinicians were assigned to the two versions at random and the versions differed only in one term, the difference on the perpetrator-punishment scale can be attributed to the label in this study.

Repeating an experiment with other people and in other places tests whether its result holds. Martinelli and colleagues (2020) repeated parts of the design in the Netherlands with 361 care professionals, who were randomly assigned to vignettes that used one of four ways of referring to a person with an alcohol or drug addiction, depression or schizophrenia. They reported no significant differences in stigmatizing attitudes between the language conditions, apart from one blame scale in the drug addiction vignette on which person-first language drew higher scores, and called for more research on the effect of language on other groups, such as people with these conditions.

Other studies examined different terms and audiences. The two tabs that follow summarize two of them.

Ashford, Brown and Curtis (2018) recruited 1,288 participants through ResearchMatch, an online research registry, and assigned them to groups that saw different terms. Participants completed a timed word-association task that measures automatic, or implicit, associations, and a vignette-based measure of social distance. The terms “substance abuser”, “addict”, “alcoholic” and “opioid addict” were strongly associated with negative words. “Recurrence of use” had a stronger positive association than “relapse”, and “pharmacotherapy” was more positive than “medication-assisted treatment”. The authors supported calls to stop using the first four terms.

McGinty, Goldman, Pescosolido and Barry (2015) tested whole stories about people. They randomly assigned 3,940 adults from a national online panel to read one of ten vignettes, which included a control vignette and portrayals of people with mental illness or drug addiction. Portrayals of people with untreated, symptomatic heroin addiction heightened negative attitudes. Portrayals of people whose prescription painkiller addiction or heroin addiction had been successfully treated led to less desire for social distance, greater belief that treatment works and less willingness to discriminate. The study suggests that how a story frames a person’s condition, including whether recovery is shown as possible, shapes public attitudes.

Reading an experiment on language

Randomized vignette studies can show whether a word changes judgements in the moment, because randomization balances everything except the word. Their limits are worth stating. They measure ratings of a hypothetical person, which may differ from how a clinician treats a real patient. Case 1.3 and the two studies in the tabs were conducted by researchers based in the United States, and the Dutch study that repeated the 2010 design did not find the same effect, so results may differ between countries, professions and wordings. In Kelly and Westerhoff’s study the term changed one of three scales, so the effect was specific to blame and punishment.

A careful summary is therefore that the experimental evidence is mixed. In one US study a stigmatizing label increased clinicians’ judgements of blame and punishment, while a Dutch study that repeated the design found no such effect; other studies found strong negative associations with terms such as “addict” and less negative public attitudes after portrayals of successful treatment. A 2022 narrative review concluded that stigmatizing language may contribute to poorer treatment outcomes for people with opioid use disorder (Werder et al., 2022), but whether changing terms changes clinical care or policy outcomes remains an evolving research question.

The experimental evidence concerns individual judgements. The focus now widens to laws and public agencies.

9.1 How Words Written into Law Shape Drug Policy

Policies begin with a description of a problem. If drug use is described as a crime, the natural responses are policing and punishment; if it is described as a health and social issue, the natural responses are prevention, treatment and support. The CCSA argues that non-stigmatizing terms in conversations with decision makers encourage “unbiased, effective policies and programs” (Canadian Centre on Substance Use and Addiction, 2019). As of October 2026, Canadian law contains an explicit statement of this kind.

In 2022, Parliament added a declaration of principles to the Controlled Drugs and Substances Act as section 10.1. It states that “problematic substance use should be addressed primarily as a health and social issue”, that interventions should “protect the health, dignity and human rights of individuals who use drugs”, and that “criminal sanctions imposed in respect of the possession of drugs for personal use can increase the stigma associated with drug use and are not consistent with established public health evidence” (Controlled Drugs and Substances Act, 1996, s. 10.1). The next section, 10.2, directs a peace officer, before laying a charge for simple possession, to consider taking no further action, giving a warning or, with the person’s consent, making a referral to a program or service. In this case the wording of the statute names the stigma created by criminal sanctions, a form of structural stigma, as a reason to change practice. Lesson 11 examines the other drug law reforms of 2022, including the repeal of mandatory minimum penalties, and Lesson 12 weighs decriminalization.

9.2 Naming Deaths: Overdose, Toxicity or Poisoning

The words used for deaths from drugs have changed over the past decade, and Canadian agencies use more than one term. The three tabs that follow describe the main options and the arguments for each.

“Overdose” is a widely understood English term, common in health care and in international campaigns. International Overdose Awareness Day, convened by the Penington Institute, considered the alternatives and decided in 2024 to keep “overdose”, describing it as broad, accurate and well recognized and defining it as an event in which the body cannot process the substance taken (International Overdose Awareness Day, 2024).

As of October 2026, several Canadian agencies described deaths by the toxicity of the drug. The BC Coroners Service published a report titled Illicit Drug Overdose Deaths in B.C. in 2018; in October 2026 its reporting was titled Unregulated Drug Toxicity Deaths (BC Coroners Service, 2026b). The Public Health Agency of Canada reports “apparent opioid toxicity deaths” and describes a “toxic drug crisis” (Public Health Agency of Canada, 2026). These terms place the cause in the content of the drug supply.

Some families and advocates prefer “poisoning”. The Overdose Awareness Day statement summarized their reasons: “overdose” can wrongly suggest dependence or addiction and so bring shame and blame, while “poisoning” draws attention to a contaminated supply. The same statement noted a risk on the other side: in the United States, the language of poisoning has been used to argue for harsher criminal penalties (International Overdose Awareness Day, 2024).

The debate shows that a term can carry more than one policy message. “Poisoning” can shift blame away from the person who died and toward the supply, and it can also be used to support harsher criminal penalties. This course uses “drug toxicity death” when following Canadian agency usage, and “overdose” when describing the physiological event, which Lesson 5 explains.

9.3 Metaphors, History and Measurement

Other words carry policy histories. The “war on drugs” is a historical policy term whose military metaphor framed drug use as an enemy to be defeated; Lesson 11 examines that policy. Lesson 2 shows how anti-Asian racism and racialized language shaped the Opium Act of 1908 and the drug panics of the 1920s. Language also affects measurement: as Section 3 noted, Health Canada revised the 2025 Canadian Substance Use Survey questionnaire partly to reduce stigma, a change that may also affect how openly people answer.

Interactive 1.4 asks you to revise eight sentences. Several have more than one defensible answer, and the feedback explains the reasoning behind the recommended choice.

Interactive 1.4
Revise the language
For each hypothetical sentence, choose the wording that follows the guidance in Table 1.7 and Canadian agency usage. Then select “Check my choices”.

10.1 Applying the Lesson: British Columbia’s 2025 Toxic Drug Data

The task that follows brings the four sections of the lesson to bear on one set of Canadian figures from 2025.

Applying this lesson: Reading British Columbia’s 2025 toxic drug data

On 19 February 2026, the BC Coroners Service reported that 1,826 people died of unregulated drug toxicity in British Columbia in 2025. The figure was preliminary and about 21 percent lower than the 2,315 deaths of 2024, and 69 percent of the people who died were aged 30 to 59 (BC Coroners Service, 2026a). The 2025 Canadian Substance Use Survey estimated that 0.1 percent of people aged 15 and older in the provinces had used heroin in the past year and that fewer than 0.05 percent had used nitazenes (Health Canada, 2026). Use the four sections of this lesson to interpret these figures.

  1. Categories (Section 1). Name the legal category of the opioids involved in most of these deaths, and explain what the coroner’s word “unregulated” adds to that category.
  2. Spectrum (Section 2). Place the use of an opioid from the unregulated market on Health Canada’s spectrum, and state which feature of the pattern creates most of the risk.
  3. Patterns (Section 3). Explain why a household survey cannot tell you how many people use the drugs involved in these deaths, naming at least three groups the survey misses and one other data source that would help.
  4. Language (Section 4). Write a two-sentence summary of the coroner’s figures for a general audience. Use person-first language and the agency’s own term for the deaths, and name one word you chose to avoid and why.

Summary

This section defined stigma as negative attitudes, beliefs or behaviours toward a group because of its situation, and distinguished self, social and structural stigma. It set out the person-first terms recommended by Health Canada and the CCSA, and explained why groups such as VANDU may choose other names for themselves. In Kelly and Westerhoff’s randomized study, the label “substance abuser” increased clinicians’ judgements of personal culpability and support for punishment, but a Dutch study that repeated the design did not find the same effect. Other studies examined implicit associations and public attitudes, and whether changing words changes care and policy remains an evolving research question. Language shapes policy through the descriptions written into law, such as section 10.1 of the Controlled Drugs and Substances Act, and through the terms agencies use for deaths. Complete the reflection below, then continue to the final assessment, which draws on all four sections of the lesson.

Key Takeaways

  • 8.1 Health Canada defines stigma as negative attitudes, beliefs or behaviours about or towards a group of people because of their situation in life. Self stigma is internalized shame, social stigma is negative attitudes and behaviour from others, and structural stigma is policies that increase stigma and barriers to help; the CCSA argues that stigmatizing language discourages people from seeking help, and a 2023 scoping review concluded that stigma among health professionals affects the care of people with substance use disorders.
  • 8.2 Person-first language acknowledges someone as a person before describing a health condition, so Health Canada and the CCSA recommend “people who use drugs”, “substance use disorder”, “positive or negative test” and “recurrence of use” in place of “addict”, “abuse” and “clean” or “dirty”. Groups such as VANDU may name themselves differently to claim an identity and a political voice, and respectful practice uses the names people choose for themselves.
  • 8.3 In Kelly and Westerhoff’s (2010) randomized study of 516 clinicians, the label “substance abuser” increased agreement with personal culpability and punishment, with no difference on social threat or victim-treatment. A Dutch study that repeated the design did not find the same effect. Other studies examined implicit associations and portrayals of successful treatment, but vignette studies measure judgements of hypothetical people, and whether changing words changes care and policy remains an evolving research question.
  • 9.1 Policies begin with a description of a problem. Since 2022, section 10.1 of the Controlled Drugs and Substances Act has stated that problematic substance use should be addressed primarily as a health and social issue and that criminal sanctions for personal possession can increase stigma, and section 10.2 directs peace officers to consider alternatives to a charge for simple possession.
  • 9.2 As of October 2026, several Canadian agencies reported drug toxicity deaths, which places the cause in the drug supply, while International Overdose Awareness Day decided in 2024 to keep “overdose” and some families prefer “poisoning”. A term can carry more than one policy message: “poisoning” shifts blame toward the supply but has also been used to argue for harsher criminal penalties.
  • 9.3 The “war on drugs” used a military metaphor that framed drug use as an enemy to be defeated, and racialized language shaped the Opium Act of 1908 and the drug panics of the 1920s. Language also affects measurement: Health Canada revised the 2025 survey questionnaire partly to reduce stigma.
  • 10.1 British Columbia’s 1,826 deaths from unregulated drug toxicity in 2025 can be read through all four lenses: the legal category and unregulated supply of the opioids involved, the higher-risk place of that use on the spectrum, the limits of a household survey that estimates heroin use at 0.1 percent, and a person-first summary that uses the coroner’s own term for the deaths.

Reflection

Kelly and Westerhoff (2010) randomly assigned 516 clinicians attending two mental health conferences to read one of two versions of a short vignette. The versions were identical except that one described the person as “a substance abuser” and the other as “having a substance use disorder”. Clinicians who read “substance abuser” agreed more strongly that the person was personally culpable and that punitive measures should be taken; the groups did not differ on perceived social threat or on support for treatment. In 2022, section 10.1 of the Controlled Drugs and Substances Act stated that criminal sanctions for possession of drugs for personal use “can increase the stigma associated with drug use”. In 150 to 250 words, explain what the experiment shows and one thing it cannot show, then rewrite this sentence using person-first language and Canadian agency terms: “Another junkie died of an overdose after relapsing; his last urine test was dirty.” Explain one choice you made in your rewrite.

Model answer

Because the clinicians were randomly assigned and the vignettes differed only in one term, the experiment shows that in this study the label itself caused the difference: calling someone a “substance abuser” made these highly trained clinicians more inclined to blame and punish. The effect was specific, appearing on one of three scales.

What it cannot show is whether the label changes what clinicians actually do. The study measured ratings of a hypothetical person at a conference and did not observe the care given to real patients, and it was conducted by researchers in the United States, so the size of the effect in Canadian clinics is uncertain. A Dutch study that repeated the design with care professionals did not find the same effect, which is a further reason not to assume that the result holds everywhere.

Rewrite: “A man who used drugs died of unregulated drug toxicity after a recurrence of opioid use; his last urine test was positive for opioids.”

The choice I want to explain is “died of unregulated drug toxicity”. It is the BC Coroners Service’s term, and it places the cause in a drug supply whose content he could not know. The original sentence placed the blame on him twice, through “junkie” and “relapsing”, and the word “another” made his death sound unremarkable. Section 10.1 of the Act recognizes that this kind of framing, written into law as punishment, can increase stigma.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: In Kelly and Westerhoff’s (2010) randomized study of 516 clinicians, what effect did the term “substance abuser” have compared with “having a substance use disorder”?

The groups differed only on the perpetrator-punishment scale: the “substance abuser” label raised agreement with personal culpability and punishment. There was no difference on social threat, so the first distractor reverses the finding, and there was no difference in support for treatment.

Question 2: How does Health Canada define structural stigma?

Health Canada defines structural stigma as policies in health and social services that increase stigma and barriers to help. Internalized messages describe self stigma, and negative attitudes from other people describe social stigma, which is the most tempting confusion.

Question 3: Which revision of “His drug screen was dirty and he relapsed” follows the guidance of Health Canada and the CCSA?

Test results are described as positive or negative, and “recurrence of use” carried a stronger positive association than “relapse” in Ashford and colleagues’ study. The option that keeps “dirty” fixes only half the sentence; the CCSA advises against “clean” and “dirty”.

Question 4: Which statement about terms for drug-related deaths is supported by this lesson?

The Public Health Agency of Canada reports apparent opioid toxicity deaths and the BC Coroners Service reports unregulated drug toxicity deaths, while International Overdose Awareness Day decided in 2024 to keep “overdose”. The BC Coroners Service titled a 2018 report Illicit Drug Overdose Deaths in B.C., so its terms have changed.
Section 5 of 5

Final Assessment

⏱ Estimated time: 25 minutes

Bringing It All Together

This lesson began with a simple question, what counts as a drug, and found that the answer depends on which of three meanings is intended. Pharmacology defines a drug by its action on the mind, so caffeine, alcohol, cannabis and fentanyl are all psychoactive substances. Canadian law sorts the same substances into regulated products, prescribed controlled medicines and controlled substances whose possession without authorization is an offence, and those categories depend on source, schedule and date as much as on chemistry. An influential UK expert panel found that its harm scores matched legal status poorly, although turning harm rankings directly into law raises problems of its own, and research on comparing drug harms is still evolving.

Health Canada’s spectrum moved the focus from the substance to the pattern of use, from non-use through beneficial, lower-risk and higher-risk use to substance use disorder. Its boundaries are drawn by guidelines that combine evidence with judgements about acceptable risk, as the shift from the 2011 drinking guidelines to the 2023 Guidance shows. National surveys then showed how these patterns are distributed: in 2025, 84 percent of people aged 15 and older in Canada used at least one substance, alcohol and cannabis dominated, and use of illegal drugs peaked among young adults. The same surveys have missed the territories, institutions, reserves and people without stable housing, which is why harm surveillance, drug checking and community-governed data are needed alongside them.

Language connects the four sections. The words used for people, behaviours, test results and deaths carry judgements. In one randomized experiment a stigmatizing label shifted clinicians toward blame and punishment, although a Dutch study that repeated the design did not find the same effect. The words written into laws, such as section 10.1 of the Controlled Drugs and Substances Act, frame substance use as a matter for health or for criminal justice. The rest of the course uses this vocabulary to examine how drugs act, why people use them and how societies govern them.

Key Takeaways from this lesson

  1. A psychoactive substance is any substance that changes mental processes such as perception, mood or cognition, whether it is legal, prescribed or illegal.
  2. The main drug classes are depressants, inhalants, opioids, stimulants, cannabis, psychedelics and dissociatives, and some substances have effects that cross classes. Canadian law sorts substances through the Controlled Drugs and Substances Act schedules, the Cannabis Act, the Tobacco and Vaping Products Act and provincial alcohol laws, and the same substance can be legal or illegal depending on its source.
  3. Legal categories are socially constructed; an influential expert panel found that its harm rankings matched legal classes poorly, although a single harm score cannot settle how drugs should be scheduled.
  4. Health Canada’s spectrum describes non-use, beneficial use, lower-risk use, higher-risk use and substance use disorder, and people can move between stages over time.
  5. The boundary of lower-risk use is set by guidelines that combine evidence with a chosen level of acceptable risk, as the 2023 Guidance on Alcohol and Health shows. The DSM-5 diagnoses substance use disorder when at least 2 of 11 criteria occur within 12 months, with severity rated mild, moderate or severe, and Canadian survey data from 2025 suggest that most people who use substances do not meet that definition.
  6. In 2025, 84 percent of people aged 15 and older in Canada used at least one substance in the past year; globally, 316 million people used a drug other than alcohol or tobacco in 2023.
  7. Canadian household and school surveys have missed people in the territories, institutions and First Nations communities on reserve and people without stable housing, so surveillance, drug checking and community-governed data are needed to describe where harms concentrate.
  8. Experiments on stigmatizing labels have found mixed effects on clinicians’ judgements of blame and punishment, and person-first language is the default when writing about other people.
  9. Agency terms for deaths and the wording of laws, such as section 10.1 of the Controlled Drugs and Substances Act, shape drug policy.
  10. Categories, the spectrum, survey evidence and language together explain a case such as British Columbia’s toxic drug deaths better than any one of them alone.

Core Concepts Reviewed

Section 1: psychoactive substance, the three meanings of “drug”, drug classes, controlled substances and schedules, prohibition, decriminalization, legal regulation and the social construction of legal categories.

Section 2: Health Canada’s substance use spectrum, beneficial, lower-risk and higher-risk use, the standard drink, the 2023 Guidance on Alcohol and Health, and DSM-5 substance use disorder.

Section 3: prevalence and time windows, weighting and confidence intervals, the Canadian Substance Use Survey and student survey, the UNODC World Drug Report 2025, sampling frames and the groups surveys miss.

Section 4: self, social and structural stigma, person-first language, Kelly and Westerhoff’s randomized vignette study, section 10.1 of the Controlled Drugs and Substances Act and the terms used for drug-related deaths.

The final reflection asks you to bring the four lenses of the lesson together in a profile of one substance.

Reflection

Choose either cannabis or alcohol and write a profile of 200 to 300 words that uses all four lenses of this lesson. Include (1) its drug class and its legal category in Canada as of 2026; (2) one example each of lower-risk use and higher-risk use on Health Canada’s spectrum, citing the relevant Canadian guideline; (3) its past-year prevalence among people aged 15 and older and among people aged 18 to 24 in the 2025 Canadian Substance Use Survey, with the overall prevalence converted into an estimated number of people; and (4) one sentence in person-first language describing people who use it, plus one term you would avoid. Facts: cannabis has been legally regulated under the Cannabis Act since 17 October 2018; its 2025 past-year prevalence was 32.5 percent overall and 50.4 percent at ages 18 to 24; Canada’s Lower-Risk Cannabis Use Guidelines advise delaying use until after adolescence and avoiding high-potency products, frequent use and smoking. Alcohol is regulated mainly by provincial and territorial laws; its 2025 past-year prevalence was 77.1 percent overall and 76.7 percent at ages 18 to 24; Canada’s Guidance on Alcohol and Health (2023) describes 2 or fewer standard drinks a week as low risk, 3 to 6 as moderate and 7 or more as increasingly high, and links more than 2 drinks on one occasion to injuries and violence. The 2025 survey represented 34.9 million people aged 15 and older.

Model answer

Cannabis in Canada: a four-lens profile. Cannabis is a psychoactive substance that acts mainly on cannabinoid receptors, and pharmacologists treat it as its own class. Since 17 October 2018 it has been legally regulated under the Cannabis Act: adults may buy it from licensed stores and possess up to the equivalent of 30 grams of dried cannabis in public, but possessing cannabis they know is illicit remains an offence. Its legal category therefore depends on its source as well as on the plant.

On Health Canada’s spectrum, an adult who uses a legal, low-potency product a few times a year without smoking it fits lower-risk use, as described by the Lower-Risk Cannabis Use Guidelines. A teenager who uses high-potency extracts every day, or anyone who drives after using, is at the higher-risk stage.

In the 2025 Canadian Substance Use Survey, 32.5 percent of people aged 15 and older reported past-year use. Applying Equation 1.2, 0.325 × 34.9 million is about 11.3 million people. Among people aged 18 to 24 the figure was 50.4 percent, the highest of any age group. These estimates exclude the territories and people without stable phone access, so they may understate use in some groups.

In my own writing I would say: “Many people who use cannabis do so occasionally and without harm, and a smaller group develops a cannabis use disorder.” I would avoid the term “stoner”, because it reduces a person to a single behaviour, the pattern Health Canada and the CCSA ask writers to avoid.

Minimum 30 characters required.

✓ Reflection saved

Final Knowledge Assessment

Final Assessment, this lesson: Drugs and Society: Concepts, Patterns of Use and Language (15 Questions)

Question 1: A person takes hydromorphone exactly as prescribed after surgery. Which description combines the legal category and the spectrum stage correctly?

Hydromorphone is a Schedule I controlled substance that is possessed legally when prescribed, and Health Canada gives taking medication as prescribed as its first example of beneficial use. It becomes illicit only when obtained without authorization.

Question 2: Which pair shows most clearly that legal status in Canada depends on the source of a substance as well as on the substance itself?

Section 8(1)(b) of the Cannabis Act makes it an offence for an adult to possess cannabis they know is illicit, while the same adult may legally possess licensed cannabis. The other pairs compare different substances with the same status, so they say nothing about source.

Question 3: Which statement about British Columbia’s decriminalization exemption is accurate as of October 2026?

The exemption covered possession of up to 2.5 grams combined of opioids, cocaine, methamphetamine and MDMA from 31 January 2023 and ended on 31 January 2026. Decriminalization removes criminal penalties for possession and does not legalize sale, which is legal regulation.

Question 4: Why did the boundary of lower-risk drinking in Canada move between the 2011 guidelines and the 2023 Guidance?

The final report cites new evidence, especially on cancer, and explains that the 2023 continuum uses a 1 in 1,000 lifetime risk as low and 1 in 100 as the upper limit of moderate risk. The standard drink (13.45 grams of pure alcohol) did not change, and the DSM-5 concerns diagnosis, not drinking guidelines.

Question 5: Using Equation 1.2, about how many people does a past-year prevalence of 10.1 percent represent in a population of 34.9 million?

N = 0.101 × 34.9 million = 3.5 million, which matches Health Canada’s estimate for any illegal or other substance of concern in 2025. Reading the percentage directly as millions gives 10.1 million, and misplacing the decimal point gives 0.35 million.

Question 6: Which feature of the Canadian Substance Use Survey means its confidence intervals may look narrower than they should?

Health Canada explains that random telephone recruitment gives no information about non-respondents, so standard non-response adjustments cannot be applied and intervals can look more precise than they are. Weighting is a strength of the design and does not cause this problem.

Question 7: According to Table 1.5 (Canadian Substance Use Survey, 2025), which pattern describes past-year cannabis use by age?

Cannabis use was 50.4 percent at ages 18 to 24 and fell steadily to 16.8 percent at 65 and older. Alcohol use is the measure that stays similar across adult age groups, and use at ages 15 to 17 (29.0 percent) was lower than among young adults.

Question 8: Which statement best distinguishes substance use disorder from higher-risk use on Health Canada’s spectrum?

Higher-risk use describes a harmful pattern or context, such as binge drinking or impaired driving, while substance use disorder is a clinical diagnosis requiring at least 2 of 11 criteria in 12 months. Higher-risk use includes legal substances such as alcohol, so the first distractor is false.

Question 9: Which data source would best show what is actually in the unregulated drug supply?

Drug checking tests what samples actually contain. Surveys record what people believe they used and how often, so they cannot reveal unexpected contents, and the UNODC estimate counts people, not drug contents.

Question 10: A news article states, “Addicts are flooding the emergency department.” Which revision best follows the lesson’s guidance while staying accurate?

Health Canada lists addicts, drug abusers and users among terms to avoid and recommends people who use drugs. The revision also drops the flood metaphor, which frames people as a threat; the other options keep a stigmatizing label.

Question 11: Which statement about the evidence on stigmatizing language is most accurate?

Kelly and Westerhoff found that a label shifted clinicians’ judgements of blame and punishment, but a Dutch study that repeated the design did not find the same effect, and the lesson describes effects on care and policy as an evolving research question. Because the 2010 study did find an effect among clinicians, the studies do not agree that labels have no effect, and no study in the lesson links terms to deaths.

Question 12: Section 10.1 of the Controlled Drugs and Substances Act, added in 2022, is an example of which idea from the lesson?

Section 10.1 states that problematic substance use should be addressed primarily as a health and social issue and that criminal sanctions for personal possession can increase stigma. It addresses structural stigma in law; it does not permit sales or list new substances.

Question 13: Which description of caffeine is consistent with Section 1?

Caffeine is a stimulant and is psychoactive; Health Canada regulates how much may be added to foods and advises adults to consume no more than 400 milligrams a day. Legal status says nothing about psychoactive effect, which is the lesson’s central point about categories.

Question 14: The UNODC estimated that 64 million people had drug use disorders in 2023. What share of them received any drug-related treatment?

The World Drug Report 2025 states that just 1 in 12 people with drug use disorders received some form of drug-related treatment, and among women the figure was 1 in 18.

Question 15: VANDU describes itself as a “grassroots democratic organization of drug users”. How does the lesson interpret this?

The lesson treats person-first language as the default when writing about others and recognizes that a group naming itself is claiming an identity and a voice. That does not license outsiders to apply the same label to other people, so the last option overgeneralizes.
✦ Complete the final reflection above before submitting

Congratulations!

You have successfully completed this lesson: Drugs and Society: Concepts, Patterns of Use and Language.

You can now define a psychoactive substance, classify common substances by drug class and by Canadian legal category, place patterns of use on Health Canada’s spectrum, read prevalence estimates from Canadian and global surveys with an eye to who they miss, and choose language that describes people who use substances accurately and without stigma.

Lesson 2, Drugs in History, asks how substances became licit or illicit in the first place. It follows tobacco, alcohol, coffee, opium and coca across cultures and eras, examines temperance and alcohol prohibition, and traces Canada’s first drug laws, from the Opium Act of 1908 to the Le Dain Commission.

Continue to Lesson 2 →
Reference

Glossary: Key Terms, People & Frameworks

📚 Reference page, available throughout the lesson

These terms, frameworks and people appear in Lesson 1; select a term in the reading to see a short definition.

Core Concepts
Psychoactive substance A substance that, when taken, affects mental processes such as perception, consciousness, cognition, mood or emotion. Caffeine, alcohol, cannabis and opioids are all psychoactive.
Drug class A group of substances with similar main effects and mechanisms, such as depressants, opioids, stimulants, cannabis, psychedelics, dissociatives and inhalants.
Controlled substance A substance listed in a schedule of the Controlled Drugs and Substances Act, so that its possession, trafficking or production is restricted by law.
Schedule A legal list of substances that attaches particular rules to them. In Canada, possession of Schedule I to III substances without authorization is an offence.
Licit and illicit A licit substance is produced, sold or held as the law permits; an illicit one is outside what the law permits. The same molecule can be either, depending on its source.
Unregulated drug supply Drugs produced and sold outside any legal system of quality control, so that their content and strength are unknown to the people who use them.
Prohibition A policy in which producing, selling and possessing a substance are criminal offences except for authorized medical or scientific purposes.
Decriminalization Removing criminal penalties for possessing small amounts of a substance for personal use while production and sale remain illegal, as in British Columbia from 2023 to 2026.
Legal regulation A policy in which production and sale of a substance are legal under licence, with rules on buyers, products and promotion, as for alcohol, tobacco and cannabis in Canada.
Section 56 exemption An exemption from the Controlled Drugs and Substances Act granted by the federal Minister for a medical or scientific purpose or in the public interest.
Social construction The idea that categories such as legal drug, medicine and illicit drug are created by people, laws and institutions and change over time, while the substances’ chemistry stays the same.
Beneficial use Substance use with positive health, social or spiritual effects, such as taking medication as prescribed or ceremonial use of tobacco.
Lower-risk use Substance use with minimal impact on the person and others, usually defined as use within guidelines such as Canada’s Guidance on Alcohol and Health.
Higher-risk use Substance use with harmful effects on the person or others, such as binge drinking, impaired driving, combining substances or using drugs from the unregulated supply.
Substance use disorder A clinical condition diagnosed when at least 2 of 11 DSM-5 criteria, such as loss of control and continued use despite harm, occur within 12 months; rated mild, moderate or severe.
Polysubstance use Using two or more substances at the same time or on the same occasion; reported by 19 percent of people aged 15 and older in Canada in 2025.
Standard drink In Canada, 17.05 millilitres (13.45 grams) of pure alcohol, the amount in a 341-millilitre bottle of 5 percent beer or a 142-millilitre glass of 12 percent wine.
Prevalence The share of a population that reports a behaviour or has a condition during a stated period, such as past-year cannabis use.
Confidence interval A range around a survey estimate that reflects uncertainty from sampling; it does not account for people outside the sampling frame or for inaccurate answers.
Sampling frame The list or method from which a survey draws its participants; people outside it cannot be selected.
Stigma Negative attitudes, beliefs or behaviours about or toward a group of people because of their situation in life (Health Canada).
Structural stigma Policies in health and social services, and laws, that increase stigma and create barriers to getting help.
Person-first language Language that names the person before a characteristic or health condition, such as “person who uses drugs”.
Drug toxicity death A death caused by the toxic effects of a drug; Canadian agencies use the term to place the cause in the content of the drug supply.
Frameworks & Tools
Controlled Drugs and Substances Act Canada’s main federal drug law, assented to in 1996, which lists controlled substances in schedules and, since 2022, includes a declaration of principles in section 10.1.
Cannabis Act The federal law in force since 17 October 2018 that legally regulates cannabis for adults and leaves sale to the provinces and territories.
Health Canada substance use spectrum A 2022 infographic arranging patterns of use as non-use, beneficial use, lower-risk use, higher-risk use and addiction (substance use disorder).
Canada’s Guidance on Alcohol and Health CCSA guidance released in January 2023 that describes a continuum of risk from weekly drinking and replaced the 2011 Low-Risk Alcohol Drinking Guidelines.
DSM-5 The fifth edition of the American Psychiatric Association’s diagnostic manual (May 2013), which combined substance abuse and dependence into substance use disorder.
Canadian Substance Use Survey Health Canada’s survey of people aged 15 and older in the provinces, run every two years; the 2025 cycle had 36,061 respondents.
Key People
David J. Nutt Lead author of a 2010 Lancet study in which a UK expert panel scored 20 drugs on 16 harm criteria and ranked alcohol as the most harmful overall.
Jonathan P. Caulkins Lead author of a 2011 critique arguing that a single harm ranking cannot decide how drugs should be scheduled.
Catherine Paradis Lead author of the 2023 final report of Canada’s Guidance on Alcohol and Health, published by the CCSA.
John F. Kelly Lead author of a 2010 randomized study of the terms “substance abuser” and “substance use disorder”, conducted at the Center for Addiction Medicine, Massachusetts General Hospital.
No matching entries. Try a different search term.